Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Feb. 18, 2015 | Jun. 30, 2014 | |
Document and Entity Information | |||
Entity Registrant Name | BioTelemetry, Inc. | ||
Entity Central Index Key | 1574774 | ||
Document Type | 10-K | ||
Document Period End Date | 31-Dec-14 | ||
Amendment Flag | FALSE | ||
Current Fiscal Year End Date | -19 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Accelerated Filer | ||
Entity Public Float | $163,218,174 | ||
Entity Common Stock, Shares Outstanding | 26,734,569 | ||
Document Fiscal Year Focus | 2014 | ||
Document Fiscal Period Focus | FY |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current assets: | ||
Cash and cash equivalents | $20,007 | $22,151 |
Accounts receivable, net of allowance for doubtful accounts of $10,347 and $7,555 at December 31, 2014 and 2013, respectively | 15,184 | 11,437 |
Other accounts receivable, net of allowance for doubtful accounts of $315 and $85 at December 31, 2014 and 2013, respectively | 9,362 | 5,680 |
Inventory | 2,566 | 2,554 |
Prepaid expenses and other current assets | 2,352 | 2,433 |
Total current assets | 49,471 | 44,255 |
Property and equipment, net | 21,703 | 18,779 |
Intangible assets, net | 22,720 | 7,312 |
Goodwill | 29,596 | 16,469 |
Other assets | 1,288 | 731 |
Total assets | 124,778 | 87,546 |
Current liabilities: | ||
Accounts payable | 13,195 | 8,718 |
Accrued liabilities | 18,460 | 8,190 |
Current portion of capital leases | 480 | 187 |
Current portion of long term debt | 938 | |
Deferred revenue | 2,248 | 1,945 |
Total current liabilities | 35,321 | 19,040 |
Deferred tax liability | 1,258 | 767 |
Long term portion of capital leases | 388 | 469 |
Long term debt | 23,070 | |
Deferred rent | 1,065 | 441 |
Total liabilities | 61,102 | 20,717 |
Shareholders' equity: | ||
Common stock-$.001 par value as of December 31, 2014 and 2013; 200,000,000 shares authorized as of December 31, 2014 and 2013; 26,693,248 and 25,812,754 shares issued and outstanding at December 31, 2014 and 2013, respectively | 27 | 26 |
Paid-in capital | 267,236 | 260,597 |
Accumulated deficit | -203,587 | -193,794 |
Total shareholders' equity | 63,676 | 66,829 |
Total liabilities and shareholders' equity | $124,778 | $87,546 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
CONSOLIDATED BALANCE SHEETS | ||
Accounts receivable-patient services, allowance for doubtful accounts (in dollars) | $10,347 | $7,555 |
Other accounts receivable, allowance for doubtful accounts (in dollars) | $315 | $85 |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 26,693,248 | 25,812,754 |
Common stock, shares outstanding | 26,693,248 | 25,812,754 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Revenues: | |||
Patient services | $133,178 | $100,386 | $93,640 |
Research services | 19,744 | 20,329 | 8,333 |
Product | 13,656 | 8,786 | 9,521 |
Total revenues | 166,578 | 129,501 | 111,494 |
Cost of revenues: | |||
Patient services | 54,942 | 34,179 | 36,793 |
Research services | 10,646 | 11,317 | 3,726 |
Product | 7,526 | 4,935 | 5,074 |
Total cost of revenues | 73,114 | 50,431 | 45,593 |
Gross profit | 93,464 | 79,070 | 65,901 |
Operating expenses: | |||
General and administrative | 45,131 | 36,569 | 32,644 |
Sales and marketing | 28,805 | 26,275 | 25,604 |
Bad debt expense | 9,347 | 7,787 | 11,912 |
Research and development | 7,396 | 7,338 | 4,664 |
Integration, restructuring and other charges | 7,098 | 7,982 | 4,236 |
Total operating expenses | 97,777 | 85,951 | 79,060 |
Loss from operations | -4,313 | -6,881 | -13,159 |
Other (loss) income (net) | -7,793 | -223 | 52 |
Loss before income taxes | -12,106 | -7,104 | -13,107 |
Benefit (provision) from income taxes | 2,313 | -215 | 905 |
Net loss | -9,793 | -7,319 | -12,202 |
Net loss per common share: | |||
Basic and diluted (in dollars per share) | ($0.37) | ($0.29) | ($0.49) |
Weighted average number of common shares outstanding: | |||
Basic and diluted (in shares) | 26,444,626 | 25,543,646 | 24,933,656 |
Unrealized gains/(losses) on securities: | |||
Unrealized holding gains/(losses) arising during the period | 16 | ||
Comprehensive loss | ($9,793) | ($7,319) | ($12,186) |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Operating activities | |||
Net loss | ($9,793) | ($7,319) | ($12,202) |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||
Provision for doubtful accounts | 9,347 | 7,787 | 11,912 |
Depreciation | 8,858 | 9,978 | 8,037 |
Increase (decrease) in deferred rent | 355 | -215 | -198 |
Deferred income tax (benefit) expense | -2,499 | 53 | -1,033 |
Stock-based compensation | 4,037 | 3,303 | 3,747 |
Amortization of intangibles | 3,692 | 2,340 | 1,341 |
Loss on extinguishment of debt | 203 | ||
Amortization of investment premium | 268 | ||
Changes in operating assets and liabilities: | |||
Accounts receivable | -12,795 | -4,597 | -3,635 |
Inventory | 299 | 340 | -885 |
Prepaid expenses and other assets | -128 | -637 | 691 |
Accounts payable | 47 | 2,369 | 552 |
Accrued and other liabilities | 7,188 | -2,143 | -2,852 |
Net cash provided by operating activities | 8,811 | 11,259 | 5,743 |
Investing activities | |||
Acquisition of businesses, net of cash acquired | -14,100 | -28,155 | |
Purchases of property and equipment and investment in internally developed software | -12,781 | -8,169 | -5,962 |
Purchases of short-term available-for-sale investments | -11,935 | ||
Sale or maturity of short-term available-for-sale investments | 39,636 | ||
Net cash used in investing activities | -26,881 | -8,169 | -6,416 |
Financing activities | |||
Proceeds from the exercise of employee stock options and employee stock purchase plan contributions | 1,051 | 847 | 440 |
Issuance of long-term debt | 41,838 | ||
Repayment of long-term debt | -26,434 | ||
Principal payments on capital lease obligations | -529 | -84 | |
Net cash provided by financing activities | 15,926 | 763 | 440 |
Net (decrease) increase in cash and cash equivalents | -2,144 | 3,853 | -233 |
Cash and cash equivalents - beginning of period | 22,151 | 18,298 | 18,531 |
Cash and cash equivalents - end of period | 20,007 | 22,151 | 18,298 |
Supplemental disclosure of cash flow information | |||
Cash paid for interest | 856 | 132 | 295 |
Cash paid for taxes | 148 | 112 | 135 |
Capital lease obligations | $737 |
CONSOLIDATED_STATEMENTS_OF_SHA
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $) | Common Stock | Paid-in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total |
In Thousands, except Share data, unless otherwise specified | |||||
Balance at Dec. 31, 2011 | $25 | $252,261 | ($16) | ($174,273) | $77,997 |
Balance (in shares) at Dec. 31, 2011 | 24,534,601 | ||||
Increase (Decrease) in Shareholders' Equity | |||||
Exercise of stock options and purchase of shares related to the employee stock purchase plan | 440 | 440 | |||
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares) | 194,878 | ||||
Stock based compensation | 3,747 | 3,747 | |||
Stock based compensation (in shares) | 459,861 | ||||
Net loss | -12,202 | -12,202 | |||
Changes in unrealized gain on available-for-sale investments | 16 | 16 | |||
Balance at Dec. 31, 2012 | 25 | 256,448 | -186,475 | 69,998 | |
Balance (in shares) at Dec. 31, 2012 | 25,189,340 | ||||
Increase (Decrease) in Shareholders' Equity | |||||
Exercise of stock options and purchase of shares related to the employee stock purchase plan | 1 | 846 | 847 | ||
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares) | 348,681 | ||||
Stock based compensation | 3,303 | 3,303 | |||
Stock based compensation (in shares) | 274,733 | ||||
Net loss | -7,319 | -7,319 | |||
Balance at Dec. 31, 2013 | 26 | 260,597 | -193,794 | 66,829 | |
Balance (in shares) at Dec. 31, 2013 | 25,812,754 | ||||
Increase (Decrease) in Shareholders' Equity | |||||
Exercise of stock options and purchase of shares related to the employee stock purchase plan | 1 | 1,050 | 1,051 | ||
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares) | 503,036 | ||||
Stock based compensation | 4,037 | 4,037 | |||
Stock based compensation (in shares) | 195,437 | ||||
Issuance of stock related to business combinations | 1,552 | 1,552 | |||
Issuance of stock related to business combinations (in shares) | 182,021 | ||||
Net loss | -9,793 | -9,793 | |||
Balance at Dec. 31, 2014 | $27 | $267,236 | ($203,587) | $63,676 | |
Balance (in shares) at Dec. 31, 2014 | 26,693,248 |
Organization_and_Description_o
Organization and Description of Business | 12 Months Ended |
Dec. 31, 2014 | |
Organization and Description of Business | |
Organization and Description of Business | 1. Organization and Description of Business |
        BioTelemetry, Inc. ("BioTelemetry," "Company", "we," "our" or "us"), a Delaware corporation, was formerly known as CardioNet, Inc. CardioNet, Inc. was reorganized under a holding company structure with the new name BioTelemetry, Inc. effective July 31, 2013. On August 1, 2013, we continued trading on The NASDAQ Global Select under the symbol "BEAT.". | |
        BioTelemetry, Inc. provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since we became focused on cardiac monitoring in 1999, we have developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour monitoring service centers. | |
        We operate under three reportable segments: (1) Patient Services, (2) Product and (3) Research Services. The Patient Services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. We offer cardiologists and electrophysiologists with a full spectrum of solutions which provides them with a single source of cardiac monitoring services. These services range from the differentiated MCT service marketed as Mobile Cardiac Outpatient TelemetryTM ("MCOT™") or External Cardiac Ambulatory Telemetry ("ECAT"),"), to wireless and trans telephonic event, Holter, Pacemaker and International Normalized Ratio ("INR") monitoring. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. | |
        In June 2014, we completed the acquisition of the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. RadCore is included in the Research Services segment. | |
        In April 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. BMS is primarily included in the Patient Services segment. | |
        In January 2014, we completed the acquisition of Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, the "Mednet entities"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. Mednet entities are included in the Patient Services and Product segment. | |
        In August 2012, we completed the acquisition of Cardiocore Lab, Inc. ("Cardiocore"). Cardiocore is a central core laboratory that provides cardiac monitoring services for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. Cardiocore is included in our Research Services segment. | |
        In February 2012, we completed the acquisition of ECG Scanning & Medical Services, Inc. ("ECG Scanning"). Similar to our core Patient Services segment, ECG Scanning was engaged in providing cardiac monitoring services to general practitioners, internal medicine specialists, cardiologists and hospital cardiac care departments. ECG Scanning is included in our Patient Services segment. | |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Summary of Significant Accounting Policies | |||||||||||
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies | ||||||||||
Principles of Consolidation | |||||||||||
        The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. | |||||||||||
Use of Estimates | |||||||||||
        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. | |||||||||||
Fair Value of Financial Instruments | |||||||||||
        The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the carrying value also approximates fair value as of December 31, 2014 (classified as Level 2). The Company did not have any Level 3 assets or liabilities for the periods ended December 31, 2014 and 2013. | |||||||||||
Cash and Cash Equivalents | |||||||||||
        Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk. | |||||||||||
Accounts Receivable and Allowance for Doubtful Accounts | |||||||||||
        Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. | |||||||||||
        Other receivables related to the Product and Research Services segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account. | |||||||||||
        We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Patient Services segment, we wrote off $6,494 and $7,919 of receivables for the years ended December 31, 2014 and 2013, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Product and Research Services segments. Additionally, we recorded bad debt expense of $9,347, $7,787 and $11,912 for the years ended December 31, 2014, 2013, and 2012, respectively. Unfavorable adjustments of $782 and $1,480 were made to accounts receivable in 2014 and 2013, respectively, related to prior years accounts receivable. | |||||||||||
Concentrations of Credit Risk | |||||||||||
        Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased. | |||||||||||
        At December 31, 2014, 2013 and 2012, one customer, Medicare, accounted for 16%, 18% and 20%, respectively, of our net accounts receivable. | |||||||||||
Inventory | |||||||||||
        Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market. | |||||||||||
Property and Equipment | |||||||||||
        Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred. | |||||||||||
Impairment of Long-Lived Assets | |||||||||||
        We periodically evaluate the recoverability of the carrying value of our long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value. | |||||||||||
Goodwill and Acquired Intangible Assets | |||||||||||
        Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded. | |||||||||||
        For the purpose of performing our goodwill impairment analysis in 2014, we consider our business to be comprised of three reporting units, Patient Services, Product and Research Services. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units. | |||||||||||
Revenue Recognition | |||||||||||
        We recognize approximately 80% of our total revenue from patient monitoring services in our Patient Services segment. We receive a significant portion of our revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements. | |||||||||||
        Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2014, 2013 and 2012, revenue from Medicare as a percentage of total revenue was 32%, 35% and 37%, respectively. | |||||||||||
        Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed. | |||||||||||
        Research Services revenue includes revenue for research and core laboratory services. Our Research Services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed. | |||||||||||
        For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor- specific or third-party evidence is unavailable. | |||||||||||
        We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities. | |||||||||||
Research and Development Costs | |||||||||||
        Research and development costs are charged to expense as incurred. | |||||||||||
Net Loss | |||||||||||
        We compute net loss per share in accordance with ASC 260, Earnings Per Share. The following summarizes the potential outstanding common stock as of the end of each period: | |||||||||||
                                                                                                                                                                                    | |||||||||||
December 31, | December 31, | December 31, | |||||||||
2014 | 2013 | 2012 | |||||||||
Employee stock purchase plan estimated share options outstanding | 39,232Â | 81,848Â | 50,903Â | ||||||||
Common stock options and restricted stock units ("RSUs") outstanding | 4,115,486Â | 3,993,590Â | 3,669,103Â | ||||||||
Common stock available for grant | 2,262,168Â | 1,761,840Â | 1,442,434Â | ||||||||
Common stock | 26,693,248Â | 25,812,754Â | 25,189,340Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | 33,110,134Â | 31,650,032Â | 30,351,780Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs. | |||||||||||
        The following table presents the calculation of historical basic and diluted net loss per share: | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year Ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
(in thousands, except per share amounts) | |||||||||||
Numerator: | |||||||||||
Net loss | $ | (9,793 | ) | $ | (7,319 | ) | $ | (12,202 | ) | ||
Denominator: | |||||||||||
Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Basic and diluted net loss per share | $ | (0.37 | ) | $ | (0.29 | ) | $ | (0.49 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014, 2013 and 2012. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014, 2013 and 2012. | |||||||||||
Stock-Based Compensation | |||||||||||
        ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.  | |||||||||||
Income Taxes | |||||||||||
        We account for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not. | |||||||||||
Segment Information | |||||||||||
        ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance. | |||||||||||
        We report our business under three segments: Patient Services, Product and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and Product sales. In addition, we realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research Services segment. | |||||||||||
Recent Accounting Pronouncements | |||||||||||
        In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which we expect to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on the consolidated financial statements. | |||||||||||
        In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendment did not have a material impact on our results of operations, cash flows, or financial position. | |||||||||||
Business_Combinations
Business Combinations | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Business Combinations | ||||||||
Business Combinations | 3. Business Combinations | |||||||
RadCore Lab, LLC | ||||||||
        On June 3, 2014, we acquired the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens our offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. We paid $400 in cash at closing and 22,513 shares of our common stock, valued at $200 at closing. While this acquisition provides growth potential, the acquisition of RadCore did not have a material effect on our financial condition, results of operations or cash flows. | ||||||||
Biomedical Systems Corporation | ||||||||
        On April 3, 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation's ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. The acquisition gave us access to internally developed Holter software and to established customer relationships. We paid $8,000 in cash at closing and 62,859 shares of our common stock, valued at $650 at closing. While the acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition, BMS did not have a material effect on our results of operations or cash flows. | ||||||||
        The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and identifiable intangible assets. The Company will complete the accounting for the BMS acquisition within a year of the acquisition date. | ||||||||
                                                                                                                                                                                    | ||||||||
Fair value of assets acquired: | ||||||||
Property and equipment | $ | 882Â | ||||||
Goodwill | 3,559Â | |||||||
Intangible assets | 4,209Â | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Net assets acquired | $ | 8,650Â | ||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
        While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following: | ||||||||
                                                                                                                                                                                    | ||||||||
Estimated | Fair Value | |||||||
Useful Life | ||||||||
(Years) | ||||||||
Customer relationships | 15Â | $ | 2,100Â | |||||
Technology | 4Â | 1,849Â | ||||||
Covenants not to compete | 7Â | 260Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
Total intangible assets | $ | 4,209Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​  | |
        Goodwill recorded in connection with this acquisition is attributable to synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Patient Services segment. | ||||||||
Mednet Healthcare Technologies, Inc. | ||||||||
        On January 31, 2014, we acquired Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, "Mednet"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. The acquisition gave us access to established customer relationships. Upon the closing of the transaction, we acquired all of the issued and outstanding capital stock, and Mednet became a wholly-owned subsidiary. We paid $5,500 in cash at closing and 96,649 shares of our common stock, valued at $705 at closing. In addition, as a result of the acquisition, we assumed indebtedness from Mednet in the aggregate amount of $9,720, including interest. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. | ||||||||
        The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and liabilities acquired, as well as identifiable intangible assets. The Company expects to complete the accounting for the Mednet acquisition within a year of the acquisition date. | ||||||||
                                                                                                                                                                                    | ||||||||
Fair value of assets acquired: | ||||||||
Cash and cash equivalents | $ | (199 | ) | |||||
Accounts receivable | 3,879 | |||||||
Inventory | 311 | |||||||
Property and equipment | 3,429 | |||||||
Goodwill | 9,354 | |||||||
Intangible assets | 9,220 | |||||||
Other assets | 317 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Total assets acquired | 26,311 | |||||||
Liabilities assumed: | ||||||||
Accounts payable | 4,427 | |||||||
Accrued expenses | 2,932 | |||||||
Other liabilities | 3,027 | |||||||
Long-term debt, capital leases, note payable and related interest | 9,720 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Total liabilities assumed | 20,106 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Net assets acquired | $ | 6,205 | ||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
        While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following: | ||||||||
                                                                                                                                                                                    | ||||||||
Estimated | Fair Value | |||||||
Useful Life | ||||||||
(Years) | ||||||||
Customer relationships | 13Â | $ | 6,500Â | |||||
Technology | 5Â | 1,600Â | ||||||
Covenants not to compete | 5Â | 420Â | ||||||
Indefinite-lived trade name | 700Â | |||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
Total intangible assets | $ | 9,220Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​  | |
        Goodwill recorded in connection with this acquisition is attributable to the assembled workforce and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Patient Services segment. | ||||||||
        The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of January 31, 2014. The pro forma information presented below does not include anticipated synergies or certain other expected benefits of the acquisition and should not be used as a predictive measure of our future results of operations. Mednet contributed $23,355 in revenue for the twelve months ended December 31, 2014. | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Revenue | $ | 170,076 | $ | 155,415 | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Net Loss | $ | (8,014 | ) | $ | (8,604 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Net loss per common share: | ||||||||
Basic and Diluted | $ | (0.30 | ) | $ | (0.34 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Weighted average number of shares: | ||||||||
Basic | 26,444,626 | 25,640,295 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Cardiocore Lab, Inc. | ||||||||
        On August 29, 2012, we entered into a definitive merger agreement with Cardiocore Lab, Inc. ("Cardiocore"), a Delaware corporation. Upon the closing of the transaction, Cardiocore became a wholly-owned subsidiary. We paid an aggregate purchase price of $23,500 in cash at closing. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. | ||||||||
        Cardiocore is engaged in central core laboratory services that provide cardiac monitoring for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. The acquisition gave us access to industry expertise, an established operating structure and a substantial footprint in the core laboratory industry. | ||||||||
        The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of August 29, 2012. The pro forma information is based on historical results adjusted for the effect of purchase accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results. | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2012 | ||||||||
Revenue | $ | 124,698 | ||||||
​ | ​ | ​  | ​  | ​ | ||||
Net Income (Loss) | $ | (10,936 | ) | |||||
​ | ​ | ​  | ​  | ​ | ||||
Net Income per common share: | ||||||||
Basic and Diluted | $ | (0.47 | ) | |||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
Weighted average number of shares: | ||||||||
Basic | 24,933,656 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
ECG Scanning and Medical Services, Inc. | ||||||||
        On February 10, 2012, we entered into and closed on a definitive Stock Purchase Agreement (the "Stock Purchase Agreement") with ECG Scanning and Medical Services, Inc., an Ohio corporation ("ECG Scanning"). Upon the closing of the transaction, we acquired all of the issued and outstanding capital stock, and ECG Scanning became a wholly-owned subsidiary. ECG Scanning was a provider of cardiac monitoring services in the United States. We paid an aggregate cash purchase price of $5,800 at closing and up to an additional $600 in cash, with an estimated fair value of $570, upon the achievement of certain performance targets approximately one year from the date of purchase. At December 31, 2012, the estimated fair value of the earn-out was $0. The reduction of the liability was recognized in the Statement of Operations and Comprehensive Income (Loss) in the Integration, restructuring, and other line. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. The acquisition gave us access to established customer relationships, and entry into additional regions and geographic locations. | ||||||||
Inventory
Inventory | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Inventory | ||||||||
Inventory | 4. Inventory | |||||||
        Inventory consists of the following: | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Raw materials and supplies | $ | 2,347Â | $ | 2,404Â | ||||
Finished goods | 219Â | 150Â | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total inventories | $ | 2,566Â | $ | 2,554Â | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method. | ||||||||
Property_and_Equipment
Property and Equipment | 12 Months Ended | |||||||||
Dec. 31, 2014 | ||||||||||
Property and Equipment | ||||||||||
Property and Equipment | 5. Property and Equipment | |||||||||
        Property and equipment consists of the following: | ||||||||||
                                                                                                                                                                                    | ||||||||||
December 31, | ||||||||||
Estimated | ||||||||||
Useful Life | ||||||||||
(Years) | 2014 | 2013 | ||||||||
Cardiac monitoring devices, device parts and components | 3Â -Â 5 | $ | 47,190 | $ | 37,273 | |||||
Computers and purchased software | 3Â -Â 5 | 12,614 | 13,302 | |||||||
Equipment, tools and molds | 3Â -Â 5 | 5,543 | 5,384 | |||||||
Furniture and fixtures | 7 | 1,396 | 2,863 | |||||||
Leasehold improvements | Life of lease | 2,930 | 2,665 | |||||||
Capital leases | 3Â -Â 7 | 1,884 | 737 | |||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total property and equipment, at cost | 71,557 | 62,224 | ||||||||
Less accumulated depreciation | (49,854 | ) | (43,445 | ) | ||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total property and equipment, net | $ | 21,703 | $ | 18,779 | ||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        Depreciation expense associated with property and equipment was $8,858, $9,978 and $8,037, for the years ended December 31, 2014, 2013 and 2012, respectively. | ||||||||||
Goodwill_and_Intangible_Assets
Goodwill and Intangible Assets | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Goodwill and Intangible Assets | ||||||||||||||
Goodwill and Intangible Assets | 6. Goodwill and Intangible Assets | |||||||||||||
        Goodwill was recognized at the time of our acquisitions. The carrying amount of goodwill as of December 31, 2014 and 2013 was $29,596 and $16,469, respectively. | ||||||||||||||
        The changes in the carrying amounts of goodwill by segment were as follows: | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
Reporting Segment | ||||||||||||||
Patient | Research | Product | Total | |||||||||||
Services | Services | |||||||||||||
Balance at December 31, 2013 | $ | 1,577 | $ | 11,735 | $ | 3,157 | $ | 16,469 | ||||||
Goodwill acquired during the year | 12,912 | 215 | — | 13,127 | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Balance at December 31, 2014 | $ | 14,489 | $ | 11,950 | $ | 3,157 | $ | 29,596 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        The gross carrying amounts and accumulated amortization of our intangible assets as of December 31, 2014 and 2013 are as follows: | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
December 31, | ||||||||||||||
Estimated | ||||||||||||||
Useful Life | ||||||||||||||
(Years) | 2014 | 2013 | ||||||||||||
Customer relationships | 5Â -Â 15 | $ | 10,700 | $ | 2,100 | |||||||||
Technology including internally developed software | 3Â -Â 5 | 12,649 | 4,000 | |||||||||||
Signed backlog | 1Â -Â 4 | 3,160 | 2,800 | |||||||||||
Unsigned backlog | 4 | 600 | 600 | |||||||||||
Covenants not to compete | 5Â -Â 7 | 1,040 | 360 | |||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total intangible assets, gross | 28,149 | 9,860 | ||||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Customer relationships accumulated amortization | (1,556 | ) | (722 | ) | ||||||||||
Proprietary technology accumulated amortization | (3,855 | ) | (1,902 | ) | ||||||||||
Signed backlog accumulated amortization | (1,984 | ) | (1,400 | ) | ||||||||||
Unsigned backlog accumulated amortization | (350 | ) | (200 | ) | ||||||||||
Covenants not to compete accumulated amortization | (295 | ) | (124 | ) | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total accumulated amortization | (8,040 | ) | (4,348 | ) | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Indefinite-lived trade name | 2,500 | 1,800 | ||||||||||||
In-process internally developed software | 111 | —  | ||||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total intangible assets, net | $ | 22,720 | $ | 7,312 | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||
        The estimated amortization expense for the next five years is summarized as follows at December 31, 2014: | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
2015 | $ | 4,628Â | ||||||||||||
2016 | 3,531Â | |||||||||||||
2017 | 2,828Â | |||||||||||||
2018 | 2,342Â | |||||||||||||
2019 | 1,768Â | |||||||||||||
Thereafter | 5,012Â | |||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||
Total intangibles assets, net | $ | 20,109Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​  | ||||||||||
        Amortization expense for the years ended December 31, 2014, 2013 and 2012 was $3,692, $2,340 and $1,341, respectively. The increase in amortization expense is driven by the current year acquisitions. | ||||||||||||||
        At December 31, 2014, 2013 and 2012, we performed our required annual impairment test of goodwill. Based on this impairment test, we determined that none of the reporting unit's goodwill was impaired. | ||||||||||||||
Accrued_Expenses
Accrued Expenses | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Accrued Expenses | ||||||||
Accrued Expenses | 7. Accrued Expenses | |||||||
        Accrued expenses consisted of the following: | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Accrued compensation | $ | 5,296Â | $ | 4,932Â | ||||
Accrued professional fees | 8,289Â | 1,922Â | ||||||
Accrued purchases | 977Â | 311Â | ||||||
Accrued restructuring costs | 689Â | 96Â | ||||||
Other | 3,209Â | 929Â | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | $ | 18,460Â | $ | 8,190Â | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Integration_Restructuring_and_
Integration, Restructuring and Other Charges | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Integration, Restructuring and Other Charges | |||||||||||
Integration, Restructuring and Other Charges | 8. Integration, Restructuring and Other Charges | ||||||||||
        We account for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and record the expenses in "Integration, restructuring and other charges" in our statement of operations, and record the related accrual in the "Accrued expenses" line of our balance sheet. | |||||||||||
        For the years ended December 31, 2014, 2013 and 2012, we incurred expenses related to restructuring, integration and other activities. These expenses were primarily a result of our recent patent litigation, the Civil Investigative Demand, as well as the activities surrounding our acquisitions. A summary of these expenses is as follows: | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
Legal fees | $ | 4,691Â | $ | 5,516Â | $ | 1,780Â | |||||
Severance and employee related costs | 1,738Â | 1,410Â | 1,490Â | ||||||||
Professional fees | 669Â | 492Â | 778Â | ||||||||
Expenses related to facility closure | — | 564 | — | ||||||||
Other charges | — | — | 188 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | $ | 7,098Â | $ | 7,982Â | $ | 4,236Â | |||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Shareholders_Equity
Shareholders' Equity | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||
Shareholders' Equity | ||||||||||||||||||||
Shareholders' Equity | 9. Shareholders' Equity | |||||||||||||||||||
Common Stock | ||||||||||||||||||||
        As of December 31, 2014 and 2013, we were authorized to issue 200,000,000 shares of common stock. As of December 31, 2014 and 2013, we had 26,693,248 and 25,812,754 shares outstanding, respectively. | ||||||||||||||||||||
Preferred Stock | ||||||||||||||||||||
        We maintain an unregistered blank check preferred stock class. As of December 31, 2014 and 2013, there are no shares authorized and outstanding. | ||||||||||||||||||||
Stock Based Compensation | ||||||||||||||||||||
2008 Equity Incentive Plan | ||||||||||||||||||||
        Our 2008 Equity Incentive Plan (the 2008 Option Plan) became effective on March 18, 2008. The Plan permits our Board of Directors to grant incentive stock options to employees and non-qualified stock options, restricted stock, performance stock and other stock-based incentive awards to officers, directors, employees and consultants. On that date, we began granting options to purchase shares of common stock to employees, executives, directors and consultants. Under the terms of the 2008 Option Plan, all available shares in the 2003 Option Plan's share reserve automatically roll into the 2008 Option Plan. Any cancellations or forfeitures of granted options under the 2003 Option Plan also automatically roll into the 2008 Option Plan. Beginning on January 1, 2009, and each year thereafter, the number of options available to be granted under the plan will increase by the lesser of 4% of the total number of common shares outstanding or 1,500,000 shares. | ||||||||||||||||||||
        Options granted under the 2008 Option Plan have exercise prices not less than the fair market value at the date of grant and have an expiration date of no greater than ten years from the date of grant. There is no vesting schedule provided in the 2008 Option Plan, and vesting is determined by the Board of Directors on the date of grant. | ||||||||||||||||||||
        The 2008 Equity Incentive Plan has 1,834,017 shares available for grant as of December 31, 2014. | ||||||||||||||||||||
        Stock option activity is summarized for the years ended December 31, 2014, 2013 and 2012 as follows: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Number | Weighted | |||||||||||||||||||
of Shares | Average | |||||||||||||||||||
Exercise Price | ||||||||||||||||||||
Options outstanding as of December 31, 2011 | 1,846,911 | $ | 10.11 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 1,387,560 | $ | 2.68 | |||||||||||||||||
Cancelled | (326,458 | ) | $ | 11.34 | ||||||||||||||||
Exercised | (2,252 | ) | $ | 1.61 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2012 | 2,905,761 | $ | 6.44 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 729,439 | $ | 3.24 | |||||||||||||||||
Cancelled | (393,770 | ) | $ | 5.93 | ||||||||||||||||
Exercised | (105,496 | ) | $ | 4.43 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2013 | 3,135,934 | $ | 5.83 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 582,012 | $ | 8.45 | |||||||||||||||||
Cancelled | (310,303 | ) | $ | 6.55 | ||||||||||||||||
Exercised | (156,791 | ) | $ | 3.37 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2014 | 3,250,852 | $ | 6.4 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
        A summary of total outstanding stock options as of December 31, 2014 is as follows: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||||
Range of Exercise Price | Number | Weighted | Weighted | Number | Weighted | Weighted | ||||||||||||||
Outstanding | Average | Average | Exercisable | Average | Average | |||||||||||||||
Remaining | Exercise Price | Remaining | Exercise Price | |||||||||||||||||
Contractual | Contractual | |||||||||||||||||||
Life (in years) | Life (in years) | |||||||||||||||||||
$0.70 - $7.50 | 2,478,630Â | 6.80Â | $ | 4.08Â | 1,750,230Â | 6.37Â | $ | 4.43Â | ||||||||||||
$7.51 - $15.00 | 473,475Â | 8.86Â | $ | 8.94Â | 98,945Â | 7.70Â | $ | 8.93Â | ||||||||||||
$15.01 - $22.50 | 218,347Â | 4.28Â | $ | 18.42Â | 218,347Â | 4.28Â | $ | 18.42Â | ||||||||||||
$22.51 - $31.18 | 80,400Â | 3.62Â | $ | 30.17Â | 80,400Â | 3.62Â | $ | 30.17Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
$0.70 - $31.18 | 3,250,852Â | 6.82Â | $ | 6.40Â | 2,147,922Â | 6.11Â | $ | 7.02Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        The table below summarizes certain additional information with respect to our options: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
(In thousands) | 2014 | 2013 | 2012 | |||||||||||||||||
Aggregate intrinsic value of options outstanding at year-end | $ | 15,258Â | $ | 11,183Â | $ | 46Â | ||||||||||||||
Aggregate intrinsic value of options exercisable at year-end | 9,918Â | 4,382Â | 13Â | |||||||||||||||||
Aggregate intrinsic value of options exercised during the year | 840Â | 422Â | 2Â | |||||||||||||||||
        Total cash received from the exercise of stock options for the year ended December 31, 2014, 2013 and 2012 was $529, $467 and $4, respectively. The tax benefit was fully reserved for through a tax valuation allowance. | ||||||||||||||||||||
        Restricted stock units activity is summarized for the years ended December 31, 2014, 2013 and 2012 as follows: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Number | Weighted Average | |||||||||||||||||||
of Shares | Grant Date Fair | |||||||||||||||||||
Value | ||||||||||||||||||||
Restricted stock outstanding as of December 31, 2011 | 622,080 | $ | 8.17 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 741,379 | $ | 2.82 | |||||||||||||||||
Forfeited | (69,854 | ) | $ | 3.45 | ||||||||||||||||
Vested | (530,263 | ) | $ | 8.03 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2012 | 763,342 | $ | 3.54 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 457,200 | $ | 3.52 | |||||||||||||||||
Forfeited | (82,813 | ) | $ | 3.07 | ||||||||||||||||
Vested | (280,073 | ) | $ | 4.82 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2013 | 857,656 | $ | 3.15 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 292,079 | $ | 8.48 | |||||||||||||||||
Forfeited | (89,664 | ) | $ | 3.3 | ||||||||||||||||
Vested | (195,437 | ) | $ | 6.27 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2014 | 864,634 | $ | 3.68 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
        In addition, a summary of total outstanding RSUs as of December 31, 2014 is as follows: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Range of Grant Price | RSUs | |||||||||||||||||||
Outstanding | ||||||||||||||||||||
$2.16 - $6.75 | 632,201Â | |||||||||||||||||||
$6.76 - $9.75 | 232,433Â | |||||||||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||||||||
$2.16 - $9.75 | 864,634Â | |||||||||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||||||||
​ | ​ | ​  | ​  | ​  | ||||||||||||||||
        We estimate the fair value of our share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future. | ||||||||||||||||||||
        The fair value of our stock-based awards was estimated at the date of grant using the following weighted average assumptions: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Year Ended | ||||||||||||||||||||
December 31, | ||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||
Expected volatility | 62.8Â | % | 60.3Â | % | 63.4Â | % | ||||||||||||||
Expected term (in years) | 6.49Â | 6.71Â | 6.31Â | |||||||||||||||||
Weighted average risk-free interest rate | 1.85Â | % | 1.34Â | % | 1.15Â | % | ||||||||||||||
Expected dividends | 0.0Â | % | 0.0Â | % | 0.0Â | % | ||||||||||||||
Weighted average grant date fair value per option | $ | 5.00Â | $ | 1.90Â | $ | 1.58Â | ||||||||||||||
Weighted average grant date fair value per RSU | $ | 8.43Â | $ | 3.52Â | $ | 2.82Â | ||||||||||||||
        Based on our historical experience of options and restricted stock units that cancel before becoming fully vested, we have assumed an annualized forfeiture rate of 9.7% for all options and 6.8% for restricted stock units. Under the true-up provision of ASC 718, we will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated. | ||||||||||||||||||||
        As of December 31, 2014, 2013 and 2012, the impact on our loss before income taxes as a result of stock-based compensation expense incurred was as follows: | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||
Numerator: | ||||||||||||||||||||
Stock-based compensation | $ | (4,037 | ) | $ | (3,303 | ) | $ | (3,747 | ) | |||||||||||
Denominator: | ||||||||||||||||||||
Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||||||||
Impact of stock-based compensation per share | $ | (0.15 | ) | $ | (0.13 | ) | $ | (0.15 | ) | |||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||||||||
        Total compensation cost of options granted but not yet vested at December 31, 2014, 2013 and 2012 was approximately $2,744, $2,644 and $3,433, respectively, which is expected to be recognized over a weighted average period of 2.68 years, 2.14 and 2.34 years, respectively. Unvested stock options as of December 31, 2014 and 2013 were 1,102,930 and 1,491,574, respectively. As of December 31, 2014 and 2013, the weighted average grant date fair value per unvested option was $5.19 and $3.45, respectively. | ||||||||||||||||||||
        The stock-based compensation expense related to unvested RSUs not yet recognized at December 31, 2014, 2013 and 2012 was approximately $1,979, $1,795 and $1,892, respectively, which is expected to be recognized over a weighted average period of 1.50 years, 1.31 years and 1.47 years, respectively. Unvested RSUs as of December 31, 2014 and 2013 were 864,634 and 857,656, respectively. As of December 31, 2014 and 2013, the weighted average grant date fair value per unvested RSU was $4.23 and $3.15, respectively. | ||||||||||||||||||||
Employee Stock Purchase Plan | ||||||||||||||||||||
        In July 2008, we made available an employee stock purchase plan in which substantially all of our full-time employees became eligible to participate effective March 18, 2008. Under the plan, employees may contribute through payroll deductions up to 15% of their compensation toward the purchase of our common stock, or $21, whichever is lower. The price per share is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase. Proceeds received from the issuance of shares are credited to stockholders' equity in the period that the shares are issued. In 2014, 346,245 shares were purchased in accordance with the Employee Stock Purchase Plan (ESPP). Net proceeds from the issuance of shares of common stock under the ESPP for the year ended December 31, 2014 were $871. In January 2014, the number of shares available for grant was increased by 258,240, per the ESPP plan documents. At December 31, 2014, approximately 428,151 shares remain available for purchase under the ESPP. For the years ended December 31, 2014, 2013 and 2012, we incurred ESPP expenses of $408, $211 and $182, respectively. | ||||||||||||||||||||
Option Acceleration | ||||||||||||||||||||
        On December 1, 2009, we accelerated the vesting of certain employees' unvested options that were deeply out-of-the-money. The acceleration was done because we believed that there was no longer a compensation incentive tied to performance, given the exercise price of the options that were accelerated. Consistent with ASC 718, we continued to expense the accelerated options over the remaining service period. We do not have a static policy threshold to use for determining whether an option is deeply out-of-the-money. Rather, we believe that the determination should be made in light of current market conditions, probability of stock price recovery within the remaining service period, and historical volatility of our stock price. For the purposes of this option acceleration, we determined that options that were out-of-the-money by 30% or more were deeply out-of-the-money. As a result of the option acceleration, approximately 309,000 previously unvested shares became fully vested on December 1, 2009. We incurred an expense associated with the options that were accelerated in the amount of $0, $137 and $578 for the years ended December 31, 2014, 2013 and 2012, respectively, which have been recorded in the General and administrative line of the consolidated statement of operations. | ||||||||||||||||||||
Income_Taxes
Income Taxes | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Income Taxes | |||||||||||
Income Taxes | 10. Income Taxes | ||||||||||
        We have deferred income tax assets totaling $57,314 at December 31, 2014, consisting primarily of federal and state net operating loss and credit carryforwards. Due to uncertainty regarding the ultimate realization of these net operating loss and credit carryforwards and other deferred income tax assets, we have established a full valuation allowance (net of deferred tax liabilities for indefinite lived intangibles) on our deferred tax assets and will recognize the benefits only as reassessment indicates the benefits are realizable. The determination of the required valuation allowance against net deferred tax assets was made without taking into account the deferred tax liabilities created from the book and tax differences on indefinite-lived assets. | |||||||||||
        Our income tax benefit for 2014 of $2,313 primarily relates to a tax benefit due to the release of the Company's valuation allowance in the amount of $2,499 resulting from the corresponding recognition of a deferred tax liability on Mednet's opening balance sheet in accordance with ASC 805, Business Combinations. | |||||||||||
        We performed an analysis to determine the extent to which we can use our net operating loss carryforwards and other deferred tax assets in future periods, subject to certain limitations imposed by the Internal Revenue Code. We concluded that largely because of our cumulative history of pre-tax losses in the most current three year period, it cannot predict that the benefits of the net operating loss carryforwards will be realized in future periods, and therefore we continue to provide a full valuation allowance for net deferred tax assets (exclusive of deferred tax liabilities for indefinite lived intangibles). We will perform a similar analysis during 2015 to reassess the ability to realize the net operating loss carryforwards and other deferred tax assets in the future | |||||||||||
        Deferred taxes result from temporary differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities are as follows: | |||||||||||
                                                                                                                                                                                    | |||||||||||
December 31, | |||||||||||
2014 | 2013 | ||||||||||
Deferred tax assets: | |||||||||||
Net operating loss carryforwards | $ | 38,540 | $ | 37,335 | |||||||
Research & development and AMT credit carryforwards | 5,314 | 4,687 | |||||||||
Stock option grants | 7,410 | 6,533 | |||||||||
Allowance for doubtful accounts | 4,532 | 3,101 | |||||||||
Other, net | 1,518 | 1,928 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred tax assets | 57,314 | 53,584 | |||||||||
Less valuation allowance | (52,998 | ) | (50,979 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Net deferred tax assets | $ | 4,316 | $ | 2,605 | |||||||
Deferred tax liabilities: | |||||||||||
Property, plant and equipment | (360 | ) | (345 | ) | |||||||
Identified intangible assets | (3,756 | ) | (2,089 | ) | |||||||
Indefinite lived intangible assets | (987 | ) | (730 | ) | |||||||
Prepaid insurance | (200 | ) | (171 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred tax liabilities | (5,303 | ) | (3,335 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Net deferred tax liability | (987 | ) | (730 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||
        Reconciliations between expected income taxes computed at the federal rate of 35% for each of the years ended December 31, 2014, 2013 and 2012, and the provision (benefit) for income taxes is as follows: | |||||||||||
                                                                                                                                                                                    | |||||||||||
Years ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
Income tax benefit at statutory rate | $ | (4,237 | ) | $ | (2,486 | ) | $ | (4,587 | ) | ||
State income tax, net of federal benefit | 4 | 716 | (211 | ) | |||||||
Stock-based compensation | 43 | 203 | 397 | ||||||||
Nondeductible goodwill impairment | — | — | — | ||||||||
Other | (258 | ) | 182 | 200 | |||||||
Increase in valuation allowance | 2,135 | 1,600 | 3,296 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Income tax (benefit) provision | $ | (2,313 | ) | $ | 215 | $ | (905 | ) | |||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        The increase in the valuation allowance in December 31, 2014 is the net of increases from the current year loss and credits generated and the release of the valuation allowance in accordance with ASC 805, Business Combinations, due to the Mednet acquisition accounting. At December 31, 2014, we had federal net operating loss carryforwards of approximately $100,997 to offset future federal taxable income expiring in various years starting in 2018 through 2034. At December 31, 2014, we had state net operating loss carryforwards of $47,776, which expire in various years starting in 2015 through 2034. Additionally, we have Research and Development credit carryforwards of $4,906 which begin to expire in 2021 through 2034. | |||||||||||
        The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The timing and manner in which we can utilize our net operating loss carryforward and future income tax deductions in any year may be limited by provisions of the Internal Revenue Code regarding the change in ownership of corporations. Such limitation may have an impact on the ultimate realization of our carryforwards and future tax deductions. Section 382 of the Internal Revenue Code ("Section 382") imposes limitations on a corporation's ability to utilize net operating losses if it experiences an "ownership change." Section 383 of the Internal Revenue Code imposes similar limitations on other tax attributes such as research and development credits. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. Any unused annual limitation may be carried over to later years, and the amount of the limitation may under certain circumstances be increased by the built-in gains in assets held by us at the time of the change that are recognized in the five-year period after the change. Currently, a portion of our loss carryforwards is limited under Section 382. | |||||||||||
        The components of our income tax (benefit) provision are summarized as follows: | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year Ended December 31, | |||||||||||
2014 | 2013 | ||||||||||
Current: | |||||||||||
Federal | $ | — | $ | 24 | |||||||
State | 186 | 138 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total current provision for income taxes | 186 | 162 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Deferred: | |||||||||||
Federal | (2,355 | ) | — | ||||||||
State | (144 | ) | 53 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred provision (benefit) for income taxes | (2,499 | ) | 53 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total provision (benefit) for income taxes | $ | (2,313 | ) | $ | 215 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||
        The U.S. Internal Revenue Service concluded its examination of our U.S. federal tax returns for all years through 2010. Because of net operating losses, our U.S. federal tax returns statutes for those years will remain subject to examination until the losses are utilized. Additionally, state tax return statutes generally remain open due to operating losses. | |||||||||||
        We do not have a tax reserve recorded for tax contingencies. As of December 31, 2014 and 2013, we have not identified any uncertain tax positions and therefore, it has no tax reserve recorded as of December 31, 2014 and 2013. | |||||||||||
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Commitments and Contingencies | ||||||||
Commitments and Contingencies | 11. Commitments and Contingencies | |||||||
Leases | ||||||||
        We lease our principal administrative and service facilities as well as office equipment under non-cancelable operating leases expiring at various dates through 2021. The terms of the leases are renewable at the end of the lease term. Payments made under operating leases are charged to operations on a straight-line basis over the period of the lease. Differences between straight-line expense and cash payments are recognized in the deferred rent line of the balance sheet. Rent expense was $3,721, $3,622 and $2,946 for the years ended December 31, 2014, 2013 and 2012, respectively. | ||||||||
        We have entered into and acquired capital leases with various expiration dates through 2017 which were used to finance equipment, furniture and medical devices. | ||||||||
        Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2014: | ||||||||
                                                                                                                                                                                    | ||||||||
Operating | Capital | |||||||
Leases | Leases | |||||||
2015 | $ | 3,277Â | $ | 480Â | ||||
2016 | 2,941Â | 287Â | ||||||
2017 | 2,836Â | 101Â | ||||||
2018 | 2,770 | — | ||||||
2019 | 1,357 | — | ||||||
Thereafter | 1,458 | —  | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
$ | 14,639Â | $ | 868Â | |||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Credit_Agreement
Credit Agreement | 12 Months Ended | |
Dec. 31, 2014 | ||
Credit Agreement | ||
Credit Agreement | 12. Credit Agreement | |
Credit Agreement | ||
        On December 30, 2014, we entered into a Credit Agreement with GE Capital, as agent for the lenders ("Lenders"), and as a Lender and swingline lender. Pursuant to the Credit Agreement, the Lenders agreed to make loans to us as follows; (i) Term Loans in an amount of $25,000 as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed $10,000 , and (ii) Revolving Loans up to $15,000, which remain undrawn. The loan is recorded on our balance sheet in the amount of $24,008, which is net of an original issue discount of $992 related to fees paid to GE Capital. | ||
        The GE Loans bear interest at an annual rate of LIBOR plus 4.0%, subject to a LIBOR floor of 1.0%. The outstanding principal of the Term Loan will be paid as follows: | ||
• | Beginning April 1, 2015, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $312, plus accrued interest; | |
• | Beginning January 1, 2018, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $625, plus accrued interest; | |
• | Beginning October 1, 2019, the remaining $16,563 will be paid in full on or before December 30, 2019, or such earlier date upon an acceleration of the Term Loan by the Lenders upon an event of default or termination by us. | |
        The Loans are secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries as well as a pledge of 65% of the capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium. | ||
Covenants | ||
        The Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of the closing date of the agreement, we were in compliance with our covenants. | ||
Debt Extinguishment | ||
        In August 2012, we entered into a Credit and Security Agreement with MidCap Financial, LLC to provide revolving loan borrowings with a loan commitment of up to $15,000, and an option to increase to a maximum loan commitment of $30,000. We borrowed $8,000 in April 2014 to fund the BMS acquisition. If we terminated the Midcap Loan at any point prior to the loan expiration date of August 2016, we would incur a loan termination fee of 1.00% of the loan commitment due immediately preceding the termination. | ||
        In February 2014, we entered into a Credit and Security Agreement with The Bancorp Bank for an aggregate amount of $9,830. The proceeds were used to pay off the assumed debt of $8,563 associated with the Mednet acquisition and to fund Mednet's working capital needs. | ||
        In December 2014, we used the proceeds of the GE Loans to repay in full the $8,000 and $9,411 outstanding balances of the MidCap and Bancorp Loans, respectively. In connection with this repayment, we incurred a debt extinguishment loss of $372, included in Other (loss) income, net in our consolidated statements of operations. This loss includes a pre-payment penalty paid to Midcap as well as the write-off of the unamortized deferred financing fees related to the Midcap and Bancorp Loans. | ||
Employee_Benefit_Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2014 | |
Employee Benefit Plan | |
Employee Benefit Plan | 13. Employee Benefit Plan |
        We sponsor a 401(k) Retirement Savings Plan (the Plan) for all eligible employees who meet certain requirements. Participants may contribute, on a pre-tax basis, up to the maximum allowable amount pursuant to Section 401(k) of the Internal Revenue Code. We are not required to contribute to the Plan. In January 2012, we adopted an amendment to eliminate the employers' matching contribution. In January 2014, we adopted an amendment to the Plan that allowed for an employer matching contribution of 100% of the first 3% of the employees' salary, and 50% of the next 2% of the employees' salary. For the years ended December 31, 2014, 2013 and 2012, we contributed $1,483, $0 and $0, respectively. Employer contributions vest immediately. | |
Segment_Information
Segment Information | 12 Months Ended | ||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||
Segment Information | |||||||||||||||||
Segment Information | 14. Segment Information | ||||||||||||||||
        We operate under three reportable segments: Patient Services, Product, and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders with our comprehensive suite of cardiac monitoring solutions in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. Our Research Services segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. Intercompany revenue relating to the manufacturing of devices by the Product segment for the other segments is included on the intersegment revenue line. | |||||||||||||||||
        Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including research and development costs incurred by the Product segment for the benefit of the other segments as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other is the Department of Justice settlement, as well as interest expense, net and other financing expenses. We do not allocate assets to the individual segments. Mednet and BMS are primarily included in the Patient Services segment; with the product manufacturing and sales portions being included in the Product segment. RadCore is included in the Research Services segment. | |||||||||||||||||
                                                                                                                                                                                    | |||||||||||||||||
Patient | Research | Product | Corporate | Consolidated | |||||||||||||
Services | Services | and Other | |||||||||||||||
2014 | |||||||||||||||||
Revenues | $ | 133,178 | $ | 19,744 | $ | 13,656 | $ | — | $ | 166,578 | |||||||
Intersegment revenues | — | — | 7,789 | (7,789 | ) | — | |||||||||||
Income (loss) before income taxes | 27,792 | (701 | ) | 6,681 | (45,878 | ) | (12,106 | ) | |||||||||
Depreciation and amortization | 8,157 | 3,710 | 502 | 181 | 12,550 | ||||||||||||
Capital expenditures | 11,488 | 1,077 | 216 | — | 12,781 | ||||||||||||
                                                                                                                                                                                    | |||||||||||||||||
Patient | Research | Product | Corporate | Consolidated | |||||||||||||
Services | Services | and Other | |||||||||||||||
2013 | |||||||||||||||||
Revenues | $ | 100,386 | $ | 20,329 | $ | 8,786 | $ | — | $ | 129,501 | |||||||
Intersegment revenues | — | — | 6,191 | (6,191 | ) | — | |||||||||||
Income (loss) before income taxes | 27,298 | 798 | 5,307 | (40,507 | ) | (7,104 | ) | ||||||||||
Depreciation and amortization | 4,253 | 4,057 | 551 | 3,457 | 12,318 | ||||||||||||
Capital expenditures | 5,796 | 2,242 | 131 | — | 8,169 | ||||||||||||
Legal_Proceedings
Legal Proceedings | 12 Months Ended |
Dec. 31, 2014 | |
Legal Proceedings | |
Legal Proceedings | 15. Legal Proceedings |
        From time to time, in the ordinary course of business and like others in the industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority or are involved in traditional employment or business litigation. We review such requests and notices and take appropriate action. | |
        The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be projected. | |
CardioNet v. Mednet Litigation | |
        On May 8, 2012, CardioNet, Inc. filed suit against Mednet Healthcare Technologies, Inc., MedTel 24, Inc., RhythmWatch LLC, and AMI Cardiac Monitoring, Inc., in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2517-JS) for patent infringement related to the making, use, offering for sale, and sale of the Heartrak ECAT device and monitoring services. The suit asserted that the defendants were infringing CardioNet's U.S. Patent Nos. 7,212,850, 7,907,996, 6,569,095, 7,587,237 and 7,941,207. CardioNet sought an injunction against each defendant, as well as monetary damages. The defendants asserted counterclaims alleging the patents in suit were invalid and not infringed. | |
        This litigation concluded on January 31, 2014 when the Court entered a Consent Judgment declaring all five CardioNet patents valid and enforceable, and infringed by the defendants' making, using, offering to sell, or selling the Heartrak ECAT device and monitoring services. The Consent Judgment also declared that all defendants are permanently enjoined from further infringement and are required to turn over all existing inventory of the Heartrak ECAT system to CardioNet and Braemar. | |
        Simultaneously with the entry on of the consent judgment BioTelemetry, through its CardioNet subsidiary, entered into a definitive stock purchase agreement, to purchase all of the outstanding capital stock of Mednet and its affiliated entities for consideration of $5,500 in cash and 96,649 shares of our common stock, valued at $705 at closing. In addition, as a result of the acquisition, we assumed indebtedness from the Mednet entities in the aggregate amount of $9,720, including interest. | |
        Under the terms of the Consent Judgment entered by the Court, Medtel 24 was granted a limited, non-exclusive, license for the Heartrak ECAT system for a period of one year. On the 364th day of such license, MedTel 24 filed a Motion to Set Aside the Consent Judgment and served the Company with a Demand for Arbitration. We are vigorously defending the claim and believe it to be without merit. | |
CardioNet v. ScottCare Litigation | |
        On May 8, 2012, CardioNet, Inc. filed suit against The ScottCare Corporation and Ambucor Health Solutions, Inc. in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2516-PBT) for patent infringement under the same five CardioNet patents, as mentioned above in the Mednet litigation, related to the making, use, sale, and offering for sale of the ScottCare TeleSentry Mobile Cardiac Telemetry device and monitoring services. CardioNet is seeking an injunction against each defendant, as well as monetary damages. The ScottCare Corporation has asserted counterclaims alleging the patents in suit are invalid and not infringed. | |
        On May 10, 2013, CardioNet, Inc. and Braemar Manufacturing, LLC filed an Amended Complaint identifying Braemar as the new owner of all right, title and interest to the patents in suit with CardioNet as the exclusive licensee of these patents. Fact discovery closed on June 30, 2014, and the trial has been re-scheduled for June 8, 2015. Consistent with the accounting for contingent liabilities, no accrual has been recorded in the financial statements. We are vigorously pursuing our claims and defending against the counterclaims. | |
Civil_Investigative_Demand
Civil Investigative Demand | 12 Months Ended |
Dec. 31, 2014 | |
Civil Investigative Demand | |
Civil Investigative Demand | 16. Civil Investigative Demand |
        On August 25, 2011, we received a Civil Investigative Demand ("CID") issued by the U.S. Department of Justice, Western District of Washington. The CID states that it was issued in the course of an investigation under the Federal False Claims Act and seeks documents for the period January 1, 2007 through the date of the CID. The CID indicates that the investigation concerns allegations that we may have used inappropriate diagnosis codes when submitting claims for payment to Medicare for our real-time, MCOT™ services. During the second quarter of 2014, we reached an agreement in principle for a potential settlement; however, the pending settlement is subject to satisfactory negotiation and completion of a settlement agreement. As result, we recorded a non-operating charge of $6,400 in the first half of 2014. This reserve was recorded to Other (loss) income, net in the consolidated statements of operations and is included in Accrued liabilities on the balance sheet. | |
        The final outcome of any current or future litigation or governmental or internal investigations, including the potential settlement, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be projected. | |
Quarterly_Financial_Data_Unaud
Quarterly Financial Data (Unaudited) | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Quarterly Financial Data (Unaudited) | ||||||||||||||
Quarterly Financial Data (Unaudited) | 17. Quarterly Financial Data (Unaudited) | |||||||||||||
        The following tables summarize the unaudited quarterly financial data for the last two fiscal years. | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
First | Second | Third | Fourth | |||||||||||
Quarter | Quarter | Quarter | Quarter | |||||||||||
(in thousands, except per share amount) | ||||||||||||||
2014 | ||||||||||||||
Total revenues | $ | 37,162 | $ | 42,650 | $ | 43,113 | $ | 43,653 | ||||||
Gross profit | 21,644 | 23,613 | 23,678 | 24,529 | ||||||||||
Integration, restructuring and other charges | 2,980 | 1,000 | 1,045 | 2,073 | ||||||||||
(Loss) income from operations | (3,696 | ) | (401 | ) | 486 | (702 | ) | |||||||
Net loss | (4,122 | ) | (3,988 | ) | (29 | ) | (1,654 | ) | ||||||
Basic and diluted net loss per share | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.00 | ) | $ | (0.06 | ) | ||
2013 | ||||||||||||||
Total revenues | $ | 32,418 | $ | 32,104 | $ | 31,874 | $ | 33,105 | ||||||
Gross profit | 19,545 | 19,496 | 19,234 | 20,795 | ||||||||||
Integration, restructuring and other charges | 1,202 | 2,541 | 3,077 | 1,162 | ||||||||||
Income (loss) from operations | (2,034 | ) | (2,238 | ) | (2,835 | ) | 226 | |||||||
Net income (loss) | (2,087 | ) | (2,299 | ) | (2,956 | ) | 23 | |||||||
Basic and diluted net income (loss) per share | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.12 | ) | $ | 0 | |||
Subsequent_Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2014 | |
Subsequent Events | |
Subsequent Events | 18. Subsequent Events |
        None. | |
Schedule_IIAllowance_for_Doubt
Schedule II-Allowance for Doubtful Accounts | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Schedule II-Allowance for Doubtful Accounts | ||||||||||||||
Allowance for Doubtful Accounts | SCHEDULE II | |||||||||||||
                                                                                                                                                                                    | ||||||||||||||
Beginning | Additions | Deductions | Ending | |||||||||||
Balance | Charged To | From | Balance | |||||||||||
Expense | Reserve | |||||||||||||
Allowance for Doubtful Accounts | ||||||||||||||
Year ended December 31, 2014 | $ | 7,640 | $ | 9,347 | $ | (6,325 | ) | $ | 10,662 | |||||
Year ended December 31, 2013 | $ | 7,617 | $ | 7,787 | $ | (7,763 | ) | $ | 7,640 | |||||
Year ended December 31, 2012 | $ | 9,889 | $ | 11,912 | $ | (14,184 | ) | $ | 7,617 | |||||
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Summary of Significant Accounting Policies | |||||||||||
Principles of Consolidation | Principles of Consolidation | ||||||||||
        The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. | |||||||||||
Use of Estimates | Use of Estimates | ||||||||||
        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. | |||||||||||
Fair Value of Financial Instruments | Fair Value of Financial Instruments | ||||||||||
        The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the carrying value also approximates fair value as of December 31, 2014 (classified as Level 2). The Company did not have any Level 3 assets or liabilities for the periods ended December 31, 2014 and 2013. | |||||||||||
Cash and Cash Equivalents | Cash and Cash Equivalents | ||||||||||
        Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk. | |||||||||||
Accounts Receivable and Allowance for Doubtful Accounts | Accounts Receivable and Allowance for Doubtful Accounts | ||||||||||
        Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. | |||||||||||
        Other receivables related to the Product and Research Services segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account. | |||||||||||
        We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Patient Services segment, we wrote off $6,494 and $7,919 of receivables for the years ended December 31, 2014 and 2013, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Product and Research Services segments. Additionally, we recorded bad debt expense of $9,347, $7,787 and $11,912 for the years ended December 31, 2014, 2013, and 2012, respectively. Unfavorable adjustments of $782 and $1,480 were made to accounts receivable in 2014 and 2013, respectively, related to prior years accounts receivable. | |||||||||||
Concentrations of Credit Risk | Concentrations of Credit Risk | ||||||||||
        Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased. | |||||||||||
        At December 31, 2014, 2013 and 2012, one customer, Medicare, accounted for 16%, 18% and 20%, respectively, of our net accounts receivable. | |||||||||||
Inventory | Inventory | ||||||||||
        Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market. | |||||||||||
Property and Equipment | Property and Equipment | ||||||||||
        Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred. | |||||||||||
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets | ||||||||||
        We periodically evaluate the recoverability of the carrying value of our long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value. | |||||||||||
Goodwill and Acquired Intangible Assets | Goodwill and Acquired Intangible Assets | ||||||||||
        Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded. | |||||||||||
        For the purpose of performing our goodwill impairment analysis in 2014, we consider our business to be comprised of three reporting units, Patient Services, Product and Research Services. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units. | |||||||||||
Revenue Recognition | Revenue Recognition | ||||||||||
        We recognize approximately 80% of our total revenue from patient monitoring services in our Patient Services segment. We receive a significant portion of our revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements. | |||||||||||
        Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2014, 2013 and 2012, revenue from Medicare as a percentage of total revenue was 32%, 35% and 37%, respectively. | |||||||||||
        Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed. | |||||||||||
        Research Services revenue includes revenue for research and core laboratory services. Our Research Services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed. | |||||||||||
        For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor- specific or third-party evidence is unavailable. | |||||||||||
        We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities. | |||||||||||
Research and Development Costs | Research and Development Costs | ||||||||||
        Research and development costs are charged to expense as incurred. | |||||||||||
Net Loss | Net Loss | ||||||||||
        We compute net loss per share in accordance with ASC 260, Earnings Per Share. The following summarizes the potential outstanding common stock as of the end of each period: | |||||||||||
                                                                                                                                                                                    | |||||||||||
December 31, | December 31, | December 31, | |||||||||
2014 | 2013 | 2012 | |||||||||
Employee stock purchase plan estimated share options outstanding | 39,232Â | 81,848Â | 50,903Â | ||||||||
Common stock options and restricted stock units ("RSUs") outstanding | 4,115,486Â | 3,993,590Â | 3,669,103Â | ||||||||
Common stock available for grant | 2,262,168Â | 1,761,840Â | 1,442,434Â | ||||||||
Common stock | 26,693,248Â | 25,812,754Â | 25,189,340Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | 33,110,134Â | 31,650,032Â | 30,351,780Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs. | |||||||||||
        The following table presents the calculation of historical basic and diluted net loss per share: | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year Ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
(in thousands, except per share amounts) | |||||||||||
Numerator: | |||||||||||
Net loss | $ | (9,793 | ) | $ | (7,319 | ) | $ | (12,202 | ) | ||
Denominator: | |||||||||||
Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Basic and diluted net loss per share | $ | (0.37 | ) | $ | (0.29 | ) | $ | (0.49 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
        If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014, 2013 and 2012. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014, 2013 and 2012. | |||||||||||
Stock-Based Compensation | Stock-Based Compensation | ||||||||||
        ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.  | |||||||||||
Income Taxes | Income Taxes | ||||||||||
        We account for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not. | |||||||||||
Segment Information | Segment Information | ||||||||||
        ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance. | |||||||||||
        We report our business under three segments: Patient Services, Product and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and Product sales. In addition, we realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research Services segment. | |||||||||||
Recent Accounting Pronouncements | Recent Accounting Pronouncements | ||||||||||
        In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which we expect to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on the consolidated financial statements. | |||||||||||
        In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendment did not have a material impact on our results of operations, cash flows, or financial position. | |||||||||||
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Summary of Significant Accounting Policies | |||||||||||
Summary of potential outstanding common stock | |||||||||||
                                                                                                                                                                                    | |||||||||||
December 31, | December 31, | December 31, | |||||||||
2014 | 2013 | 2012 | |||||||||
Employee stock purchase plan estimated share options outstanding | 39,232Â | 81,848Â | 50,903Â | ||||||||
Common stock options and restricted stock units ("RSUs") outstanding | 4,115,486Â | 3,993,590Â | 3,669,103Â | ||||||||
Common stock available for grant | 2,262,168Â | 1,761,840Â | 1,442,434Â | ||||||||
Common stock | 26,693,248Â | 25,812,754Â | 25,189,340Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | 33,110,134Â | 31,650,032Â | 30,351,780Â | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Schedule of calculation of basic and diluted net loss per share | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year Ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
(in thousands, except per share amounts) | |||||||||||
Numerator: | |||||||||||
Net loss | $ | (9,793 | ) | $ | (7,319 | ) | $ | (12,202 | ) | ||
Denominator: | |||||||||||
Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Basic and diluted net loss per share | $ | (0.37 | ) | $ | (0.29 | ) | $ | (0.49 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Business_Combinations_Tables
Business Combinations (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
BMS | ||||||||
Business Acquisition | ||||||||
Schedule of purchase price allocation | The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. | |||||||
                                                                                                                                                                                    | ||||||||
Fair value of assets acquired: | ||||||||
Property and equipment | $ | 882Â | ||||||
Goodwill | 3,559Â | |||||||
Intangible assets | 4,209Â | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Net assets acquired | $ | 8,650Â | ||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
Schedule of estimated allocation of finite-lived intangible assets | ||||||||
                                                                                                                                                                                    | ||||||||
Estimated | Fair Value | |||||||
Useful Life | ||||||||
(Years) | ||||||||
Customer relationships | 15Â | $ | 2,100Â | |||||
Technology | 4Â | 1,849Â | ||||||
Covenants not to compete | 7Â | 260Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
Total intangible assets | $ | 4,209Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​  | |
Mednet | ||||||||
Business Acquisition | ||||||||
Schedule of purchase price allocation | The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. | |||||||
                                                                                                                                                                                    | ||||||||
Fair value of assets acquired: | ||||||||
Cash and cash equivalents | $ | (199 | ) | |||||
Accounts receivable | 3,879 | |||||||
Inventory | 311 | |||||||
Property and equipment | 3,429 | |||||||
Goodwill | 9,354 | |||||||
Intangible assets | 9,220 | |||||||
Other assets | 317 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Total assets acquired | 26,311 | |||||||
Liabilities assumed: | ||||||||
Accounts payable | 4,427 | |||||||
Accrued expenses | 2,932 | |||||||
Other liabilities | 3,027 | |||||||
Long-term debt, capital leases, note payable and related interest | 9,720 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Total liabilities assumed | 20,106 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
Net assets acquired | $ | 6,205 | ||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
Schedule of allocation of finite-lived and indefinite-lived intangible assets | ||||||||
                                                                                                                                                                                    | ||||||||
Estimated | Fair Value | |||||||
Useful Life | ||||||||
(Years) | ||||||||
Customer relationships | 13Â | $ | 6,500Â | |||||
Technology | 5Â | 1,600Â | ||||||
Covenants not to compete | 5Â | 420Â | ||||||
Indefinite-lived trade name | 700Â | |||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
Total intangible assets | $ | 9,220Â | ||||||
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​ | ​  | ​  | ​  | |
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Revenue | $ | 170,076 | $ | 155,415 | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Net Loss | $ | (8,014 | ) | $ | (8,604 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Net loss per common share: | ||||||||
Basic and Diluted | $ | (0.30 | ) | $ | (0.34 | ) | ||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Weighted average number of shares: | ||||||||
Basic | 26,444,626 | 25,640,295 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Cardiocore | ||||||||
Business Acquisition | ||||||||
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2012 | ||||||||
Revenue | $ | 124,698 | ||||||
​ | ​ | ​  | ​  | ​ | ||||
Net Income (Loss) | $ | (10,936 | ) | |||||
​ | ​ | ​  | ​  | ​ | ||||
Net Income per common share: | ||||||||
Basic and Diluted | $ | (0.47 | ) | |||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
Weighted average number of shares: | ||||||||
Basic | 24,933,656 | |||||||
​ | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​  | ||||
Inventory_Tables
Inventory (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Inventory | ||||||||
Schedule of inventory | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Raw materials and supplies | $ | 2,347Â | $ | 2,404Â | ||||
Finished goods | 219Â | 150Â | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total inventories | $ | 2,566Â | $ | 2,554Â | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Property_and_Equipment_Tables
Property and Equipment (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2014 | ||||||||||
Property and Equipment | ||||||||||
Schedule of Property and equipment | ||||||||||
                                                                                                                                                                                    | ||||||||||
December 31, | ||||||||||
Estimated | ||||||||||
Useful Life | ||||||||||
(Years) | 2014 | 2013 | ||||||||
Cardiac monitoring devices, device parts and components | 3Â -Â 5 | $ | 47,190 | $ | 37,273 | |||||
Computers and purchased software | 3Â -Â 5 | 12,614 | 13,302 | |||||||
Equipment, tools and molds | 3Â -Â 5 | 5,543 | 5,384 | |||||||
Furniture and fixtures | 7 | 1,396 | 2,863 | |||||||
Leasehold improvements | Life of lease | 2,930 | 2,665 | |||||||
Capital leases | 3Â -Â 7 | 1,884 | 737 | |||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total property and equipment, at cost | 71,557 | 62,224 | ||||||||
Less accumulated depreciation | (49,854 | ) | (43,445 | ) | ||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total property and equipment, net | $ | 21,703 | $ | 18,779 | ||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Goodwill_and_Intangible_Assets1
Goodwill and Intangible Assets (Tables) | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Goodwill and Intangible Assets | ||||||||||||||
Schedule of changes in the carrying amounts of goodwill by segment | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
Reporting Segment | ||||||||||||||
Patient | Research | Product | Total | |||||||||||
Services | Services | |||||||||||||
Balance at December 31, 2013 | $ | 1,577 | $ | 11,735 | $ | 3,157 | $ | 16,469 | ||||||
Goodwill acquired during the year | 12,912 | 215 | — | 13,127 | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Balance at December 31, 2014 | $ | 14,489 | $ | 11,950 | $ | 3,157 | $ | 29,596 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
December 31, | ||||||||||||||
Estimated | ||||||||||||||
Useful Life | ||||||||||||||
(Years) | 2014 | 2013 | ||||||||||||
Customer relationships | 5Â -Â 15 | $ | 10,700 | $ | 2,100 | |||||||||
Technology including internally developed software | 3Â -Â 5 | 12,649 | 4,000 | |||||||||||
Signed backlog | 1Â -Â 4 | 3,160 | 2,800 | |||||||||||
Unsigned backlog | 4 | 600 | 600 | |||||||||||
Covenants not to compete | 5Â -Â 7 | 1,040 | 360 | |||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total intangible assets, gross | 28,149 | 9,860 | ||||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Customer relationships accumulated amortization | (1,556 | ) | (722 | ) | ||||||||||
Proprietary technology accumulated amortization | (3,855 | ) | (1,902 | ) | ||||||||||
Signed backlog accumulated amortization | (1,984 | ) | (1,400 | ) | ||||||||||
Unsigned backlog accumulated amortization | (350 | ) | (200 | ) | ||||||||||
Covenants not to compete accumulated amortization | (295 | ) | (124 | ) | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total accumulated amortization | (8,040 | ) | (4,348 | ) | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Indefinite-lived trade name | 2,500 | 1,800 | ||||||||||||
In-process internally developed software | 111 | —  | ||||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
Total intangible assets, net | $ | 22,720 | $ | 7,312 | ||||||||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||
​ | ​ | ​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||
Summary of estimated amortization expense for the next five years | The estimated amortization expense for the next five years is summarized as follows at December 31, 2014: | |||||||||||||
                                                                                                                                                                                    | ||||||||||||||
2015 | $ | 4,628Â | ||||||||||||
2016 | 3,531Â | |||||||||||||
2017 | 2,828Â | |||||||||||||
2018 | 2,342Â | |||||||||||||
2019 | 1,768Â | |||||||||||||
Thereafter | 5,012Â | |||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||
Total intangibles assets, net | $ | 20,109Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​  | ||||||||||
Accrued_Expenses_Tables
Accrued Expenses (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Accrued Expenses | ||||||||
Schedule of accrued expenses | ||||||||
                                                                                                                                                                                    | ||||||||
December 31, | ||||||||
2014 | 2013 | |||||||
Accrued compensation | $ | 5,296Â | $ | 4,932Â | ||||
Accrued professional fees | 8,289Â | 1,922Â | ||||||
Accrued purchases | 977Â | 311Â | ||||||
Accrued restructuring costs | 689Â | 96Â | ||||||
Other | 3,209Â | 929Â | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | $ | 18,460Â | $ | 8,190Â | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Integration_Restructuring_and_1
Integration, Restructuring and Other Charges (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Integration, Restructuring and Other Charges | |||||||||||
Summary of expenses related to restructuring, integration and other activities | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
Legal fees | $ | 4,691Â | $ | 5,516Â | $ | 1,780Â | |||||
Severance and employee related costs | 1,738Â | 1,410Â | 1,490Â | ||||||||
Professional fees | 669Â | 492Â | 778Â | ||||||||
Expenses related to facility closure | — | 564 | — | ||||||||
Other charges | — | — | 188 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Total | $ | 7,098Â | $ | 7,982Â | $ | 4,236Â | |||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Shareholders_Equity_Tables
Shareholders' Equity (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||
Shareholders' Equity | ||||||||||||||||||||
Summary of stock option under all equity incentive plans | Â Â Â Â Â Â | |||||||||||||||||||
Number | Weighted | |||||||||||||||||||
of Shares | Average | |||||||||||||||||||
Exercise Price | ||||||||||||||||||||
Options outstanding as of December 31, 2011 | 1,846,911 | $ | 10.11 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 1,387,560 | $ | 2.68 | |||||||||||||||||
Cancelled | (326,458 | ) | $ | 11.34 | ||||||||||||||||
Exercised | (2,252 | ) | $ | 1.61 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2012 | 2,905,761 | $ | 6.44 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 729,439 | $ | 3.24 | |||||||||||||||||
Cancelled | (393,770 | ) | $ | 5.93 | ||||||||||||||||
Exercised | (105,496 | ) | $ | 4.43 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2013 | 3,135,934 | $ | 5.83 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 582,012 | $ | 8.45 | |||||||||||||||||
Cancelled | (310,303 | ) | $ | 6.55 | ||||||||||||||||
Exercised | (156,791 | ) | $ | 3.37 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Options outstanding as of December 31, 2014 | 3,250,852 | $ | 6.4 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Summary of total outstanding stock options | A summary of total outstanding stock options as of December 31, 2014 is as follows: | |||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||||
Range of Exercise Price | Number | Weighted | Weighted | Number | Weighted | Weighted | ||||||||||||||
Outstanding | Average | Average | Exercisable | Average | Average | |||||||||||||||
Remaining | Exercise Price | Remaining | Exercise Price | |||||||||||||||||
Contractual | Contractual | |||||||||||||||||||
Life (in years) | Life (in years) | |||||||||||||||||||
$0.70 - $7.50 | 2,478,630Â | 6.80Â | $ | 4.08Â | 1,750,230Â | 6.37Â | $ | 4.43Â | ||||||||||||
$7.51 - $15.00 | 473,475Â | 8.86Â | $ | 8.94Â | 98,945Â | 7.70Â | $ | 8.93Â | ||||||||||||
$15.01 - $22.50 | 218,347Â | 4.28Â | $ | 18.42Â | 218,347Â | 4.28Â | $ | 18.42Â | ||||||||||||
$22.51 - $31.18 | 80,400Â | 3.62Â | $ | 30.17Â | 80,400Â | 3.62Â | $ | 30.17Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
$0.70 - $31.18 | 3,250,852Â | 6.82Â | $ | 6.40Â | 2,147,922Â | 6.11Â | $ | 7.02Â | ||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Summary of certain additional information with respect to options | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
(In thousands) | 2014 | 2013 | 2012 | |||||||||||||||||
Aggregate intrinsic value of options outstanding at year-end | $ | 15,258Â | $ | 11,183Â | $ | 46Â | ||||||||||||||
Aggregate intrinsic value of options exercisable at year-end | 9,918Â | 4,382Â | 13Â | |||||||||||||||||
Aggregate intrinsic value of options exercised during the year | 840Â | 422Â | 2Â | |||||||||||||||||
Summary of Restricted stock units activity | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Number | Weighted Average | |||||||||||||||||||
of Shares | Grant Date Fair | |||||||||||||||||||
Value | ||||||||||||||||||||
Restricted stock outstanding as of December 31, 2011 | 622,080 | $ | 8.17 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 741,379 | $ | 2.82 | |||||||||||||||||
Forfeited | (69,854 | ) | $ | 3.45 | ||||||||||||||||
Vested | (530,263 | ) | $ | 8.03 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2012 | 763,342 | $ | 3.54 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 457,200 | $ | 3.52 | |||||||||||||||||
Forfeited | (82,813 | ) | $ | 3.07 | ||||||||||||||||
Vested | (280,073 | ) | $ | 4.82 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2013 | 857,656 | $ | 3.15 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Granted | 292,079 | $ | 8.48 | |||||||||||||||||
Forfeited | (89,664 | ) | $ | 3.3 | ||||||||||||||||
Vested | (195,437 | ) | $ | 6.27 | ||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
Restricted stock outstanding as of December 31, 2014 | 864,634 | $ | 3.68 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |||||||||||||
Summary of total outstanding RSUs | In addition, a summary of total outstanding RSUs as of December 31, 2014 is as follows: | |||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Range of Grant Price | RSUs | |||||||||||||||||||
Outstanding | ||||||||||||||||||||
$2.16 - $6.75 | 632,201Â | |||||||||||||||||||
$6.76 - $9.75 | 232,433Â | |||||||||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||||||||
$2.16 - $9.75 | 864,634Â | |||||||||||||||||||
​ | ​ | ​  | ​  | ​ | ||||||||||||||||
​ | ​ | ​  | ​  | ​  | ||||||||||||||||
Schedule of weighted average assumptions used to estimate the fair value of the stock-based awards | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Year Ended | ||||||||||||||||||||
December 31, | ||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||
Expected volatility | 62.8Â | % | 60.3Â | % | 63.4Â | % | ||||||||||||||
Expected term (in years) | 6.49Â | 6.71Â | 6.31Â | |||||||||||||||||
Weighted average risk-free interest rate | 1.85Â | % | 1.34Â | % | 1.15Â | % | ||||||||||||||
Expected dividends | 0.0Â | % | 0.0Â | % | 0.0Â | % | ||||||||||||||
Weighted average grant date fair value per option | $ | 5.00Â | $ | 1.90Â | $ | 1.58Â | ||||||||||||||
Weighted average grant date fair value per RSU | $ | 8.43Â | $ | 3.52Â | $ | 2.82Â | ||||||||||||||
Schedule of impact of stock-based compensation on entity's loss before income taxes | ||||||||||||||||||||
                                                                                                                                                                                    | ||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||
Numerator: | ||||||||||||||||||||
Stock-based compensation | $ | (4,037 | ) | $ | (3,303 | ) | $ | (3,747 | ) | |||||||||||
Denominator: | ||||||||||||||||||||
Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | |||||||||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||||||||
Impact of stock-based compensation per share | $ | (0.15 | ) | $ | (0.13 | ) | $ | (0.15 | ) | |||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||||||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2014 | |||||||||||
Income Taxes | |||||||||||
Schedule of the components of the entity's deferred tax assets and liabilities | |||||||||||
                                                                                                                                                                                    | |||||||||||
December 31, | |||||||||||
2014 | 2013 | ||||||||||
Deferred tax assets: | |||||||||||
Net operating loss carryforwards | $ | 38,540 | $ | 37,335 | |||||||
Research & development and AMT credit carryforwards | 5,314 | 4,687 | |||||||||
Stock option grants | 7,410 | 6,533 | |||||||||
Allowance for doubtful accounts | 4,532 | 3,101 | |||||||||
Other, net | 1,518 | 1,928 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred tax assets | 57,314 | 53,584 | |||||||||
Less valuation allowance | (52,998 | ) | (50,979 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Net deferred tax assets | $ | 4,316 | $ | 2,605 | |||||||
Deferred tax liabilities: | |||||||||||
Property, plant and equipment | (360 | ) | (345 | ) | |||||||
Identified intangible assets | (3,756 | ) | (2,089 | ) | |||||||
Indefinite lived intangible assets | (987 | ) | (730 | ) | |||||||
Prepaid insurance | (200 | ) | (171 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred tax liabilities | (5,303 | ) | (3,335 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Net deferred tax liability | (987 | ) | (730 | ) | |||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||
Schedule of reconciliations between expected income taxes computed at the federal rate and the provision (benefit) for income taxes | |||||||||||
                                                                                                                                                                                    | |||||||||||
Years ended December 31, | |||||||||||
2014 | 2013 | 2012 | |||||||||
Income tax benefit at statutory rate | $ | (4,237 | ) | $ | (2,486 | ) | $ | (4,587 | ) | ||
State income tax, net of federal benefit | 4 | 716 | (211 | ) | |||||||
Stock-based compensation | 43 | 203 | 397 | ||||||||
Nondeductible goodwill impairment | — | — | — | ||||||||
Other | (258 | ) | 182 | 200 | |||||||
Increase in valuation allowance | 2,135 | 1,600 | 3,296 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
Income tax (benefit) provision | $ | (2,313 | ) | $ | 215 | $ | (905 | ) | |||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Schedule of the components of the entity's income tax (benefit) provision | |||||||||||
                                                                                                                                                                                    | |||||||||||
Year Ended December 31, | |||||||||||
2014 | 2013 | ||||||||||
Current: | |||||||||||
Federal | $ | — | $ | 24 | |||||||
State | 186 | 138 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total current provision for income taxes | 186 | 162 | |||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Deferred: | |||||||||||
Federal | (2,355 | ) | — | ||||||||
State | (144 | ) | 53 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total deferred provision (benefit) for income taxes | (2,499 | ) | 53 | ||||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
Total provision (benefit) for income taxes | $ | (2,313 | ) | $ | 215 | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | ||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | ||||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Commitments and Contingencies | ||||||||
Summary of the future minimum lease payments under non-cancelable operating and capital leases | Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2014: | |||||||
                                                                                                                                                                                    | ||||||||
Operating | Capital | |||||||
Leases | Leases | |||||||
2015 | $ | 3,277Â | $ | 480Â | ||||
2016 | 2,941Â | 287Â | ||||||
2017 | 2,836Â | 101Â | ||||||
2018 | 2,770 | — | ||||||
2019 | 1,357 | — | ||||||
Thereafter | 1,458 | —  | ||||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
$ | 14,639Â | $ | 868Â | |||||
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​ | |
​ | ​ | ​  | ​  | ​ | ​  | ​  | ​  | |
Segment_Information_Tables
Segment Information (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||
Segment Information | |||||||||||||||||
Summary of financial information concerning the entity's reportable segments | |||||||||||||||||
                                                                                                                                                                                    | |||||||||||||||||
Patient | Research | Product | Corporate | Consolidated | |||||||||||||
Services | Services | and Other | |||||||||||||||
2014 | |||||||||||||||||
Revenues | $ | 133,178 | $ | 19,744 | $ | 13,656 | $ | — | $ | 166,578 | |||||||
Intersegment revenues | — | — | 7,789 | (7,789 | ) | — | |||||||||||
Income (loss) before income taxes | 27,792 | (701 | ) | 6,681 | (45,878 | ) | (12,106 | ) | |||||||||
Depreciation and amortization | 8,157 | 3,710 | 502 | 181 | 12,550 | ||||||||||||
Capital expenditures | 11,488 | 1,077 | 216 | — | 12,781 | ||||||||||||
                                                                                                                                                                                    | |||||||||||||||||
Patient | Research | Product | Corporate | Consolidated | |||||||||||||
Services | Services | and Other | |||||||||||||||
2013 | |||||||||||||||||
Revenues | $ | 100,386 | $ | 20,329 | $ | 8,786 | $ | — | $ | 129,501 | |||||||
Intersegment revenues | — | — | 6,191 | (6,191 | ) | — | |||||||||||
Income (loss) before income taxes | 27,298 | 798 | 5,307 | (40,507 | ) | (7,104 | ) | ||||||||||
Depreciation and amortization | 4,253 | 4,057 | 551 | 3,457 | 12,318 | ||||||||||||
Capital expenditures | 5,796 | 2,242 | 131 | — | 8,169 | ||||||||||||
Quarterly_Financial_Data_Unaud1
Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Quarterly Financial Data (Unaudited) | ||||||||||||||
Summary of the unaudited quarterly financial data | ||||||||||||||
                                                                                                                                                                                    | ||||||||||||||
First | Second | Third | Fourth | |||||||||||
Quarter | Quarter | Quarter | Quarter | |||||||||||
(in thousands, except per share amount) | ||||||||||||||
2014 | ||||||||||||||
Total revenues | $ | 37,162 | $ | 42,650 | $ | 43,113 | $ | 43,653 | ||||||
Gross profit | 21,644 | 23,613 | 23,678 | 24,529 | ||||||||||
Integration, restructuring and other charges | 2,980 | 1,000 | 1,045 | 2,073 | ||||||||||
(Loss) income from operations | (3,696 | ) | (401 | ) | 486 | (702 | ) | |||||||
Net loss | (4,122 | ) | (3,988 | ) | (29 | ) | (1,654 | ) | ||||||
Basic and diluted net loss per share | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.00 | ) | $ | (0.06 | ) | ||
2013 | ||||||||||||||
Total revenues | $ | 32,418 | $ | 32,104 | $ | 31,874 | $ | 33,105 | ||||||
Gross profit | 19,545 | 19,496 | 19,234 | 20,795 | ||||||||||
Integration, restructuring and other charges | 1,202 | 2,541 | 3,077 | 1,162 | ||||||||||
Income (loss) from operations | (2,034 | ) | (2,238 | ) | (2,835 | ) | 226 | |||||||
Net income (loss) | (2,087 | ) | (2,299 | ) | (2,956 | ) | 23 | |||||||
Basic and diluted net income (loss) per share | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.12 | ) | $ | 0 | |||
Organization_and_Description_o1
Organization and Description of Business (Details) | 12 Months Ended |
Dec. 31, 2014 | |
segment | |
Organization and Description of Business | |
Number of operating segments | 3 |
Summary_of_Significant_Account3
Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Accounts receivable and allowance for doubtful accounts | |||
Bad debt expense | $9,347 | $7,787 | $11,912 |
Unfavorable adjustments related to prior year's accounts receivable | 782 | 1,480 | |
Patient Services | |||
Accounts receivable and allowance for doubtful accounts | |||
Write-off of receivables | $6,494 | $7,919 |
Summary_of_Significant_Account4
Summary of Significant Accounting Policies (Details 2) (Net accounts receivable, Credit concentration risk) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Concentrations of credit risk | |||
Number of major customers | 1 | ||
Medicare | |||
Concentrations of credit risk | |||
Concentration risk (as a percent) | 16.00% | 18.00% | 20.00% |
Summary_of_Significant_Account5
Summary of Significant Accounting Policies (Details 3) | 12 Months Ended | 30 Months Ended | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
segment | segment | |||
Goodwill and Acquired Intangible Assets | ||||
Number of reporting units | 3 | 3 | ||
Revenue | Service concentration | Patient monitoring services | ||||
Revenue Recognition | ||||
Concentration risk (as a percent) | 80.00% | |||
Revenue | Payor concentration | Medicare | ||||
Revenue Recognition | ||||
Concentration risk (as a percent) | 32.00% | 35.00% | 37.00% |
Summary_of_Significant_Account6
Summary of Significant Accounting Policies (Details 4) (USD $) | 3 Months Ended | 12 Months Ended | 30 Months Ended | |||||||||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2014 |
segment | segment | |||||||||||
Potential outstanding common stock | ||||||||||||
Employee stock purchase plan estimated share options outstanding (in shares) | 39,232 | 81,848 | 39,232 | 81,848 | 50,903 | 39,232 | ||||||
Common stock options and restricted stock units ("RSUs") outstanding (in shares) | 4,115,486 | 3,993,590 | 4,115,486 | 3,993,590 | 3,669,103 | 4,115,486 | ||||||
Common stock available for grant (in shares) | 2,262,168 | 1,761,840 | 2,262,168 | 1,761,840 | 1,442,434 | 2,262,168 | ||||||
Common stock (in shares) | 26,693,248 | 25,812,754 | 26,693,248 | 25,812,754 | 25,189,340 | 26,693,248 | ||||||
Total (in shares) | 33,110,134 | 31,650,032 | 33,110,134 | 31,650,032 | 30,351,780 | 33,110,134 | ||||||
Calculation of basic and diluted net loss per share | ||||||||||||
Numerator: Net loss (in dollars) | ($1,654) | ($29) | ($3,988) | ($4,122) | $23 | ($2,956) | ($2,299) | ($2,087) | ($9,793) | ($7,319) | ($12,202) | |
Denominator: Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 | |||||||||
Basic and diluted net loss per share | ($0.06) | $0 | ($0.15) | ($0.16) | $0 | ($0.12) | ($0.09) | ($0.08) | ($0.37) | ($0.29) | ($0.49) | |
Segment Information | ||||||||||||
Number of reportable segments | 3 | 3 |
Business_Combinations_Details
Business Combinations (Details) (RadCore, Cardiocore, USD $) | 0 Months Ended |
In Thousands, except Share data, unless otherwise specified | Jun. 03, 2014 |
RadCore | Cardiocore | |
Business Acquisition | |
Purchase consideration in cash | $400 |
Number of shares of common stock issued for acquisition | 22,513 |
Value of common stock issued for acquisition | $200 |
Business_Combinations_Details_
Business Combinations (Details 2) (USD $) | 0 Months Ended | 12 Months Ended | |
In Thousands, except Share data, unless otherwise specified | Apr. 03, 2014 | Dec. 31, 2014 | Dec. 31, 2013 |
Fair value of assets acquired: | |||
Goodwill | $29,596 | $16,469 | |
BMS | CardioNet | |||
Business Acquisition | |||
Purchase consideration in cash | 8,000 | ||
Number of shares of common stock issued for acquisition | 62,859 | ||
Value of common stock issued for acquisition | 650 | ||
Fair value of assets acquired: | |||
Property and equipment | 882 | ||
Goodwill | 3,559 | ||
Intangible assets | 4,209 | ||
Net assets acquired | 8,650 | ||
BMS | CardioNet | Customer relationships | |||
Fair value of assets acquired: | |||
Intangible assets | 2,100 | ||
Estimated Useful Life | 15 years | ||
BMS | CardioNet | Technology | |||
Fair value of assets acquired: | |||
Intangible assets | 1,849 | ||
Estimated Useful Life | 4 years | ||
BMS | CardioNet | Covenants not to compete | |||
Fair value of assets acquired: | |||
Intangible assets | $260 | ||
Estimated Useful Life | 7 years |
Business_Combinations_Details_1
Business Combinations (Details 3) (USD $) | 12 Months Ended | 0 Months Ended | |
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Jan. 31, 2014 |
Fair value of assets acquired: | |||
Goodwill | $29,596 | $16,469 | |
Mednet | |||
Liabilities assumed: | |||
Long-term debt, capital leases, note payable and related interest | 9,720 | ||
Pro-Forma Information | |||
Revenue from acquisition | 23,355 | ||
Revenue | 170,076 | 155,415 | |
Net Loss | -8,014 | -8,604 | |
Net loss per common share: Basic and Diluted (in dollars per share) | ($0.30) | ($0.34) | |
Weighted average number of shares: Basic | 26,444,626 | 25,640,295 | |
Mednet | CardioNet | |||
Business Acquisition | |||
Purchase consideration in cash | 5,500 | ||
Number of shares of common stock issued for acquisition | 96,649 | ||
Value of common stock issued for acquisition | 705 | ||
Fair value of assets acquired: | |||
Cash and cash equivalents | -199 | ||
Accounts receivable | 3,879 | ||
Inventory | 311 | ||
Property and equipment | 3,429 | ||
Goodwill | 9,354 | ||
Intangible assets | 9,220 | ||
Other assets | 317 | ||
Total assets acquired | 26,311 | ||
Liabilities assumed: | |||
Accounts payable | 4,427 | ||
Accrued expenses | 2,932 | ||
Other liabilities | 3,027 | ||
Long-term debt, capital leases, note payable and related interest | 9,720 | ||
Total liabilities assumed | 20,106 | ||
Net assets acquired | 6,205 | ||
Mednet | CardioNet | Indefinite-lived trade name | |||
Fair value of assets acquired: | |||
Intangible assets | 700 | ||
Mednet | CardioNet | Customer relationships | |||
Fair value of assets acquired: | |||
Intangible assets | 6,500 | ||
Estimated Useful Life | 13 years | ||
Mednet | CardioNet | Technology | |||
Fair value of assets acquired: | |||
Intangible assets | 1,600 | ||
Estimated Useful Life | 5 years | ||
Mednet | CardioNet | Covenants not to compete | |||
Fair value of assets acquired: | |||
Intangible assets | $420 | ||
Estimated Useful Life | 5 years |
Business_Combinations_Details_2
Business Combinations (Details 4) (USD $) | 0 Months Ended | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Aug. 29, 2012 | Dec. 31, 2012 | Dec. 31, 2014 | Dec. 31, 2013 |
Fair value of assets acquired: | ||||
Goodwill | $29,596 | $16,469 | ||
Cardiocore | ||||
Business Acquisition | ||||
Aggregate cash purchase price | 23,500 | |||
Pro-Forma Information | ||||
Revenue | 124,698 | |||
Net Income (Loss) | ($10,936) | |||
Net Income per common share: Basic and Diluted (in dollars per share) | ($0.47) | |||
Weighted average number of shares: Basic | 24,933,656 |
Business_Combinations_Details_3
Business Combinations (Details 5) (USD $) | 0 Months Ended | |||
In Thousands, unless otherwise specified | Feb. 10, 2012 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Fair value of assets acquired: | ||||
Goodwill | $29,596 | $16,469 | ||
ECG Scanning | ||||
Business Acquisition | ||||
Aggregate cash purchase price | 5,800 | |||
Additional cash to be paid upon the achievement of certain performance targets | 600 | |||
Estimated fair value | $570 | $0 | ||
Period for achievement of performance target upon which cash is required to be paid | 1 year |
Inventory_Details
Inventory (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Inventory | ||
Raw materials and supplies | $2,347 | $2,404 |
Finished goods | 219 | 150 |
Total inventories | $2,566 | $2,554 |
Property_and_Equipment_Details
Property and Equipment (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Property and equipment | |||
Total property and equipment, at cost | $71,557 | $62,224 | |
Less accumulated depreciation | -49,854 | -43,445 | |
Total property and equipment, net | 21,703 | 18,779 | |
Depreciation expense | 8,858 | 9,978 | 8,037 |
Cardiac monitoring devices, device parts and components | |||
Property and equipment | |||
Total property and equipment, at cost | 47,190 | 37,273 | |
Cardiac monitoring devices, device parts and components | Minimum | |||
Property and equipment | |||
Estimated Useful Life | 3 years | ||
Cardiac monitoring devices, device parts and components | Maximum | |||
Property and equipment | |||
Estimated Useful Life | 5 years | ||
Computers and purchased software | |||
Property and equipment | |||
Total property and equipment, at cost | 12,614 | 13,302 | |
Computers and purchased software | Minimum | |||
Property and equipment | |||
Estimated Useful Life | 3 years | ||
Computers and purchased software | Maximum | |||
Property and equipment | |||
Estimated Useful Life | 5 years | ||
Equipment, tools and molds | |||
Property and equipment | |||
Total property and equipment, at cost | 5,543 | 5,384 | |
Equipment, tools and molds | Minimum | |||
Property and equipment | |||
Estimated Useful Life | 3 years | ||
Equipment, tools and molds | Maximum | |||
Property and equipment | |||
Estimated Useful Life | 5 years | ||
Furniture and fixtures | |||
Property and equipment | |||
Estimated Useful Life | 7 years | ||
Total property and equipment, at cost | 1,396 | 2,863 | |
Leasehold improvements | |||
Property and equipment | |||
Total property and equipment, at cost | 2,930 | 2,665 | |
Capital leases | |||
Property and equipment | |||
Total property and equipment, at cost | $1,884 | $737 | |
Capital leases | Minimum | |||
Property and equipment | |||
Estimated Useful Life | 3 years | ||
Capital leases | Maximum | |||
Property and equipment | |||
Estimated Useful Life | 7 years |
Goodwill_and_Intangible_Assets2
Goodwill and Intangible Assets (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 |
Changes in the carrying amounts of goodwill by segment | ||
Balance at the beginning of the period | $16,469 | |
Goodwill acquired during the year | 13,127 | |
Balance at the end of the period | 29,596 | |
Patient Services | ||
Changes in the carrying amounts of goodwill by segment | ||
Balance at the beginning of the period | 1,577 | |
Goodwill acquired during the year | 12,912 | |
Balance at the end of the period | 14,489 | |
Research Services | ||
Changes in the carrying amounts of goodwill by segment | ||
Balance at the beginning of the period | 11,735 | |
Goodwill acquired during the year | 215 | |
Balance at the end of the period | 11,950 | |
Product | ||
Changes in the carrying amounts of goodwill by segment | ||
Balance at the beginning of the period | 3,157 | |
Balance at the end of the period | $3,157 | $3,157 |
Goodwill_and_Intangible_Assets3
Goodwill and Intangible Assets (Details 2) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Intangible assets | |||
Total intangible assets, gross | $28,149 | $9,860 | |
Total accumulated amortization | -8,040 | -4,348 | |
Total intangible assets, net | 22,720 | 7,312 | |
Estimated amortization expenses | |||
2015 | 4,628 | ||
2016 | 3,531 | ||
2017 | 2,828 | ||
2018 | 2,342 | ||
2019 | 1,768 | ||
Thereafter | 5,012 | ||
Total intangibles assets, net | 20,109 | ||
Amortization expense | 3,692 | 2,340 | 1,341 |
Indefinite-lived trade name | |||
Intangible assets | |||
Indefinite-lived trade name | 2,500 | 1,800 | |
Customer relationships | |||
Intangible assets | |||
Total intangible assets, gross | 10,700 | 2,100 | |
Total accumulated amortization | -1,556 | -722 | |
Customer relationships | Minimum | |||
Intangible assets | |||
Estimated Useful Life | 5 years | ||
Customer relationships | Maximum | |||
Intangible assets | |||
Estimated Useful Life | 15 years | ||
Technology including internally developed software | |||
Intangible assets | |||
Total intangible assets, gross | 12,649 | 4,000 | |
Total accumulated amortization | -3,855 | -1,902 | |
Technology including internally developed software | Minimum | |||
Intangible assets | |||
Estimated Useful Life | 3 years | ||
Technology including internally developed software | Maximum | |||
Intangible assets | |||
Estimated Useful Life | 5 years | ||
Signed backlog | |||
Intangible assets | |||
Total intangible assets, gross | 3,160 | 2,800 | |
Total accumulated amortization | -1,984 | -1,400 | |
Signed backlog | Minimum | |||
Intangible assets | |||
Estimated Useful Life | 1 year | ||
Signed backlog | Maximum | |||
Intangible assets | |||
Estimated Useful Life | 4 years | ||
Unsigned backlog | |||
Intangible assets | |||
Estimated Useful Life | 4 years | ||
Total intangible assets, gross | 600 | 600 | |
Total accumulated amortization | -350 | -200 | |
Covenants not to compete | |||
Intangible assets | |||
Total intangible assets, gross | 1,040 | 360 | |
Total accumulated amortization | -295 | -124 | |
Covenants not to compete | Minimum | |||
Intangible assets | |||
Estimated Useful Life | 5 years | ||
Covenants not to compete | Maximum | |||
Intangible assets | |||
Estimated Useful Life | 7 years | ||
In-process internally developed software | |||
Intangible assets | |||
In-process internally developed software | $111 |
Accrued_Expenses_Details
Accrued Expenses (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Accrued Expenses | ||
Accrued compensation | $5,296 | $4,932 |
Accrued professional fees | 8,289 | 1,922 |
Accrued purchases | 977 | 311 |
Accrued restructuring costs | 689 | 96 |
Other | 3,209 | 929 |
Total | $18,460 | $8,190 |
Integration_Restructuring_and_2
Integration, Restructuring and Other Charges (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Integration, Restructuring and Other Charges | |||||||||||
Legal fees | $4,691 | $5,516 | $1,780 | ||||||||
Severance and employee related costs | 1,738 | 1,410 | 1,490 | ||||||||
Professional fees | 669 | 492 | 778 | ||||||||
Expenses related to facility closure | 564 | ||||||||||
Other charges | 188 | ||||||||||
Total | $2,073 | $1,045 | $1,000 | $2,980 | $1,162 | $3,077 | $2,541 | $1,202 | $7,098 | $7,982 | $4,236 |
Shareholders_Equity_Details
Shareholders' Equity (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Shareholders' Equity | |||
Common stock, shares authorized | 200,000,000 | 200,000,000 | |
Common stock, shares outstanding | 26,693,248 | 25,812,754 | 25,189,340 |
Preferred stock, shares authorized | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | |
Stock-based compensation | |||
Common stock available for grant (in shares) | 2,262,168 | 1,761,840 | 1,442,434 |
2008 Option Plan | |||
Stock-based compensation | |||
Common stock available for grant (in shares) | 1,834,017 | ||
Stock options | |||
Number of Shares | |||
Balance at the beginning of the period (in shares) | 3,135,934 | 2,905,761 | 1,846,911 |
Granted (in shares) | 582,012 | 729,439 | 1,387,560 |
Cancelled (in shares) | -310,303 | -393,770 | -326,458 |
Exercised (in shares) | -156,791 | -105,496 | -2,252 |
Balance at the end of the period (in shares) | 3,250,852 | 3,135,934 | 2,905,761 |
Weighted Average Exercise Price | |||
Balance at the beginning of the period (in dollars per share) | $5.83 | $6.44 | $10.11 |
Granted (in dollars per share) | $8.45 | $3.24 | $2.68 |
Cancelled (in dollars per share) | $6.55 | $5.93 | $11.34 |
Exercised (in dollars per share) | $3.37 | $4.43 | $1.61 |
Balance at the end of the period (in dollars per share) | $6.40 | $5.83 | $6.44 |
Stock options | 2008 Option Plan | |||
Stock-based compensation | |||
Increase in the number of options available to be granted as a percentage of total number of common shares outstanding | 4.00% | ||
Increase in the number of options available to be granted (in shares) | 1,500,000 | ||
Stock options | 2008 Option Plan | Maximum | |||
Stock-based compensation | |||
Expiration period | 10 years |
Shareholders_Equity_Details_2
Shareholders' Equity (Details 2) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
$0.70 - $7.50 | |
Summary of total outstanding stock options | |
Range of exercise prices, low end of range (in dollars per share) | $0.70 |
Range of exercise prices, high end of range (in dollars per share) | $7.50 |
Options Outstanding | |
Number Outstanding (in shares) | 2,478,630 |
Weighted - Average Remaining Contractual Life | 6 years 9 months 18 days |
Weighted - Average Exercise Price (in dollars per share) | $4.08 |
Options Exercisable | |
Number Exercisable (in shares) | 1,750,230 |
Weighted - Average Remaining Contractual Life | 6 years 4 months 13 days |
Weighted - Average Exercise Price (in dollars per share) | $4.43 |
$7.51 - $15.00 | |
Summary of total outstanding stock options | |
Range of exercise prices, low end of range (in dollars per share) | $7.51 |
Range of exercise prices, high end of range (in dollars per share) | $15 |
Options Outstanding | |
Number Outstanding (in shares) | 473,475 |
Weighted - Average Remaining Contractual Life | 8 years 10 months 10 days |
Weighted - Average Exercise Price (in dollars per share) | $8.94 |
Options Exercisable | |
Number Exercisable (in shares) | 98,945 |
Weighted - Average Remaining Contractual Life | 7 years 8 months 12 days |
Weighted - Average Exercise Price (in dollars per share) | $8.93 |
$15.01 - $22.50 | |
Summary of total outstanding stock options | |
Range of exercise prices, low end of range (in dollars per share) | $15.01 |
Range of exercise prices, high end of range (in dollars per share) | $22.50 |
Options Outstanding | |
Number Outstanding (in shares) | 218,347 |
Weighted - Average Remaining Contractual Life | 4 years 3 months 11 days |
Weighted - Average Exercise Price (in dollars per share) | $18.42 |
Options Exercisable | |
Number Exercisable (in shares) | 218,347 |
Weighted - Average Remaining Contractual Life | 4 years 3 months 11 days |
Weighted - Average Exercise Price (in dollars per share) | $18.42 |
$22.51 - $31.18 | |
Summary of total outstanding stock options | |
Range of exercise prices, low end of range (in dollars per share) | $22.51 |
Range of exercise prices, high end of range (in dollars per share) | $31.18 |
Options Outstanding | |
Number Outstanding (in shares) | 80,400 |
Weighted - Average Remaining Contractual Life | 3 years 7 months 13 days |
Weighted - Average Exercise Price (in dollars per share) | $30.17 |
Options Exercisable | |
Number Exercisable (in shares) | 80,400 |
Weighted - Average Remaining Contractual Life | 3 years 7 months 13 days |
Weighted - Average Exercise Price (in dollars per share) | $30.17 |
$0.70 - $31.18 | |
Summary of total outstanding stock options | |
Range of exercise prices, low end of range (in dollars per share) | $0.70 |
Range of exercise prices, high end of range (in dollars per share) | $31.18 |
Options Outstanding | |
Number Outstanding (in shares) | 3,250,852 |
Weighted - Average Remaining Contractual Life | 6 years 9 months 26 days |
Weighted - Average Exercise Price (in dollars per share) | $6.40 |
Options Exercisable | |
Number Exercisable (in shares) | 2,147,922 |
Weighted - Average Remaining Contractual Life | 6 years 1 month 10 days |
Weighted - Average Exercise Price (in dollars per share) | $7.02 |
Shareholders_Equity_Details_3
Shareholders' Equity (Details 3) (Stock options, USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Stock options | |||
Stock-based compensation | |||
Aggregate intrinsic value of options outstanding at year-end | $15,258 | $11,183 | $46 |
Aggregate intrinsic value of options exercisable at year-end | 9,918 | 4,382 | 13 |
Aggregate intrinsic value of options exercised during the year | 840 | 422 | 2 |
Total cash received from the exercise of stock options | $529 | $467 | $4 |
Shareholders_Equity_Details_4
Shareholders' Equity (Details 4) (Restricted stock units, USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Restricted stock units | |||
Number of Shares | |||
Balance at the beginning of the period (in shares) | 857,656 | 763,342 | 622,080 |
Granted (in shares) | 292,079 | 457,200 | 741,379 |
Forfeited (in shares) | -89,664 | -82,813 | -69,854 |
Vested (in shares) | -195,437 | -280,073 | -530,263 |
Balance at the end of the period (in shares) | 864,634 | 857,656 | 763,342 |
Weighted Average Grant Date Fair Value | |||
Balance at the beginning of the period (in dollars per shares) | $3.15 | $3.54 | $8.17 |
Granted (in dollars per share) | $8.48 | $3.52 | $2.82 |
Forfeited (in dollars per share) | $3.30 | $3.07 | $3.45 |
Vested (in dollars per share) | $6.27 | $4.82 | $8.03 |
Balance at the end of the period (in dollars per shares) | $3.68 | $3.15 | $3.54 |
Shareholders_Equity_Details_5
Shareholders' Equity (Details 5) (Restricted stock units, USD $) | 12 Months Ended | |||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Stock-based compensation | ||||
RSUs Outstanding (in shares) | 864,634 | 857,656 | 763,342 | 622,080 |
$2.16 - $6.75 | ||||
Stock-based compensation | ||||
RSUs Outstanding (in shares) | 632,201 | |||
$2.16 - $6.75 | Minimum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $2.16 | |||
$2.16 - $6.75 | Maximum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $6.75 | |||
$6.76 - $9.75 | ||||
Stock-based compensation | ||||
RSUs Outstanding (in shares) | 232,433 | |||
$6.76 - $9.75 | Minimum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $6.76 | |||
$6.76 - $9.75 | Maximum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $9.75 | |||
$2.16 - $9.75 | ||||
Stock-based compensation | ||||
RSUs Outstanding (in shares) | 864,634 | |||
$2.16 - $9.75 | Minimum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $2.16 | |||
$2.16 - $9.75 | Maximum | ||||
Stock-based compensation | ||||
Grant price (in dollars per share) | $9.75 |
Shareholders_Equity_Details_6
Shareholders' Equity (Details 6) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Weighted average assumptions used to estimate the fair value of the stock-based awards | |||
Expected volatility (as a percent) | 62.80% | 60.30% | 63.40% |
Expected term | 6 years 5 months 27 days | 6 years 8 months 16 days | 6 years 3 months 22 days |
Weighted-average risk-free interest rate (as a percent) | 1.85% | 1.34% | 1.15% |
Expected dividends (as a percent) | 0.00% | 0.00% | 0.00% |
Weighted average fair value per option (in dollars per share) | $5 | $1.90 | $1.58 |
Weighted average fair value per RSU (in dollars per share) | $8.43 | $3.52 | $2.82 |
Stock options | |||
Weighted average assumptions used to estimate the fair value of the stock-based awards | |||
Future forfeiture rate (as a percent) | 9.70% | ||
Restricted stock units | |||
Weighted average assumptions used to estimate the fair value of the stock-based awards | |||
Future forfeiture rate (as a percent) | 6.80% |
Shareholders_Equity_Details_7
Shareholders' Equity (Details 7) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Stock-based compensation | |||
Stock based compensation | ($4,037) | ($3,303) | ($3,747) |
Denominator: Weighted average shares used in computing basic and diluted net loss per share | 26,444,626 | 25,543,646 | 24,933,656 |
Impact of stock-based compensation expense (in dollars per share) | ($0.15) | ($0.13) | ($0.15) |
Stock options | |||
Stock-based compensation | |||
Total compensation cost of options granted but not yet vested | 2,744 | 2,644 | 3,433 |
Weighted average remaining periods over which unrecognized amounts are expected to be recognized | 2 years 8 months 5 days | 2 years 1 month 21 days | 2 years 4 months 2 days |
Unvested awards (in shares) | 1,102,930 | 1,491,574 | |
Weighted-average grant-date fair value of unvested awards (in dollars per share) | $5.19 | $3.45 | |
Restricted stock units | |||
Stock-based compensation | |||
Stock-based compensation expense related to nonvested awards | $1,979 | $1,795 | $1,892 |
Weighted average remaining periods over which unrecognized amounts are expected to be recognized | 1 year 6 months | 1 year 3 months 22 days | 1 year 5 months 19 days |
Unvested awards (in shares) | 864,634 | 857,656 | |
Weighted-average grant-date fair value of unvested awards (in dollars per share) | $4.23 | $3.15 |
Shareholders_Equity_Details_8
Shareholders' Equity (Details 8) (USD $) | 1 Months Ended | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Jan. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Stock-based compensation | ||||
Remaining shares available under Plan | 2,262,168 | 1,761,840 | 1,442,434 | |
Expenses incurred | $4,037 | $3,303 | $3,747 | |
Employee Stock Purchase Plan | ||||
Stock-based compensation | ||||
Maximum percentage of compensation that employees may contribute through payroll deductions | 15.00% | |||
Maximum amount that employees may contribute through payroll deductions | 21 | |||
Percentage of the fair market price on the first day of the offering period or the market price as on the day of purchase | 85.00% | |||
Common stock purchased (in shares) | 346,245 | |||
Proceeds from the issuance of shares of common stock (in dollars) | 871 | |||
Increase in number of shares available for grant | 258,240 | |||
Remaining shares available under Plan | 428,151 | |||
Expenses incurred | $408 | $211 | $182 |
Shareholders_Equity_Details_9
Shareholders' Equity (Details 9) (Stock options, USD $) | 0 Months Ended | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 01, 2009 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Stock options | ||||
Option Acceleration | ||||
Threshold percentage for determining deeply out-of-the-money options | 30.00% | |||
Number of previously unvested shares, which became fully vested as a result of option acceleration | 309,000 | |||
Expense associated with the accelerated options | $0 | $137 | $578 |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Deferred tax assets: | |||
Net operating loss carryforwards | $38,540 | $37,335 | |
Research & development and AMT credit carryforwards | 5,314 | 4,687 | |
Stock option grants | 7,410 | 6,533 | |
Allowance for doubtful accounts | 4,532 | 3,101 | |
Other, net | 1,518 | 1,928 | |
Total deferred tax assets | 57,314 | 53,584 | |
Less valuation allowance | -52,998 | -50,979 | |
Net deferred tax assets | 4,316 | 2,605 | |
Deferred tax liabilities: | |||
Property, plant and equipment | -360 | -345 | |
Identified intangible assets | -3,756 | -2,089 | |
Indefinite lived intangible assets | -987 | -730 | |
Prepaid insurance | -200 | -171 | |
Total deferred tax liabilities | -5,303 | -3,335 | |
Net deferred tax liability | -987 | -730 | |
Reconciliation between expected income taxes computed at the federal rate and the provision (benefit) for income taxes | |||
Federal rate of income tax (as a percent) | 35.00% | 35.00% | 35.00% |
Income tax benefit at statutory rate | -4,237 | -2,486 | -4,587 |
State income tax, net of federal benefit | 4 | 716 | -211 |
Stock-based compensation | 43 | 203 | 397 |
Other | -258 | 182 | 200 |
Increase in valuation allowance | 2,135 | 1,600 | 3,296 |
Income tax provision (benefit) | -2,313 | 215 | -905 |
Net Operating Loss Carryforwards | |||
Minimum percentage of increase in ownership of stockholders for ownership change | 50.00% | ||
Period over which a minimum 50 percent of increase in ownership is required for ownership change | 3 years | ||
Period of recognition of built-in gains in assets held at the time of ownership change | 5 years | ||
Current: | |||
Federal | 24 | ||
State | 186 | 138 | |
Total current provision for income taxes | 186 | 162 | |
Deferred: | |||
Federal | -2,355 | ||
State | -144 | 53 | |
Total deferred provision (benefit) for income taxes | -2,499 | 53 | -1,033 |
Income tax provision (benefit) | -2,313 | 215 | -905 |
Tax reserve recorded for tax contingencies | 0 | 0 | |
Federal | |||
Net Operating Loss Carryforwards | |||
Net operating loss carryforwards | 100,977 | ||
State | |||
Net Operating Loss Carryforwards | |||
Net operating loss carryforwards | 47,776 | ||
Research and Development | |||
Net Operating Loss Carryforwards | |||
Tax credit carryforward | $4,906 |
Commitments_and_Contingencies_1
Commitments and Contingencies (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Commitments and Contingencies | |||
Rent expense | $3,721 | $3,622 | $2,946 |
Future minimum lease payments under non-cancelable operating leases | |||
2015 | 3,277 | ||
2016 | 2,941 | ||
2017 | 2,836 | ||
2018 | 2,770 | ||
2019 | 1,357 | ||
Thereafter | 1,458 | ||
Total | 14,639 | ||
Future minimum lease payments under capital leases | |||
2015 | 480 | ||
2016 | 287 | ||
2017 | 101 | ||
Total | $868 |
Credit_Agreement_Details
Credit Agreement (Details) (USD $) | 1 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 30, 2014 | Dec. 31, 2014 | Apr. 30, 2014 | Feb. 28, 2014 | Aug. 31, 2012 |
Credit Agreement | ||||||
Loss on extinguishment of debt | $372 | |||||
Mednet | ||||||
Credit Agreement | ||||||
Amount of assumed debt associated with acquisition | 8,563 | |||||
GE Capital | ||||||
Credit Agreement | ||||||
Percentage of capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium pledged to secure loan | 65.00% | |||||
GE Capital | LIBOR | ||||||
Credit Agreement | ||||||
Debt instrument, basis spread on variable rate (as a percent) | 4.00% | |||||
LIBOR floor (as a percent) | 1.00% | |||||
GE Capital | Term Loan | ||||||
Credit Agreement | ||||||
Maximum borrowing capacity | 25,000 | |||||
Additional uncommitted borrowing capacity | 10,000 | |||||
Loan balance net of original issue discount | 24,008 | |||||
Original issue discount | 992 | |||||
GE Capital | Term Loan | April 2015 to December 2017 | ||||||
Credit Agreement | ||||||
Principal amount of quarterly installment payments | 312 | |||||
GE Capital | Term Loan | January 2018 to September 2019 | ||||||
Credit Agreement | ||||||
Principal amount of quarterly installment payments | 625 | |||||
GE Capital | Term Loan | October 2019 to December 2019 | ||||||
Credit Agreement | ||||||
Remaining principal amount to be paid in full | 16,563 | |||||
GE Capital | Revolving Loan | ||||||
Credit Agreement | ||||||
Maximum borrowing capacity | 15,000 | |||||
MidCap Financial, LLC | ||||||
Credit Agreement | ||||||
Maximum borrowing capacity | 15,000 | |||||
Potential maximum loan commitment | 30,000 | |||||
Loan termination fee (as a percent) | 1.00% | |||||
Extinguishment of debt | 8,000 | |||||
MidCap Financial, LLC | BMS | ||||||
Credit Agreement | ||||||
Amount withdrawn for acquisition | 8,000 | |||||
The Bancorp Bank | ||||||
Credit Agreement | ||||||
Aggregate amount of agreement with The Bancorp Bank | 9,830 | |||||
Extinguishment of debt | $9,411 |
Employee_Benefit_Plan_Details
Employee Benefit Plan (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Employee Benefit Plan | |||
Employer's matching contribution as a percent of of the first 3% of employees' salary contributed | 100.00% | ||
Percentage of employees' salary contributed matched 100% by employer | 3.00% | ||
Employer's matching contribution as a percent of of the next 2% of employees' salary contributed | 50.00% | ||
Percentage of employees' salary contributed matched 50% by employer | 2.00% | ||
Employer's contribution | $1,483 | $0 | $0 |
Segment_Information_Details
Segment Information (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
segment | |||||||||||
Segment Information | |||||||||||
Number of operating segments | 3 | ||||||||||
Segment information | |||||||||||
Revenues | $43,653 | $43,113 | $42,650 | $37,162 | $33,105 | $31,874 | $32,104 | $32,418 | $166,578 | $129,501 | $111,494 |
Income (loss) before income taxes | -12,106 | -7,104 | -13,107 | ||||||||
Depreciation and amortization | 12,550 | 12,318 | |||||||||
Capital expenditures | 12,781 | 8,169 | |||||||||
Patient Services | |||||||||||
Segment information | |||||||||||
Revenues | 133,178 | 100,386 | |||||||||
Capital expenditures | 11,488 | 5,796 | |||||||||
Research Services | |||||||||||
Segment information | |||||||||||
Revenues | 19,744 | 20,329 | |||||||||
Capital expenditures | 1,077 | 2,242 | |||||||||
Product | |||||||||||
Segment information | |||||||||||
Revenues | 13,656 | 8,786 | |||||||||
Capital expenditures | 216 | 131 | |||||||||
Operating segments | Patient Services | |||||||||||
Segment information | |||||||||||
Income (loss) before income taxes | 27,792 | 27,298 | |||||||||
Depreciation and amortization | 8,157 | 4,253 | |||||||||
Operating segments | Research Services | |||||||||||
Segment information | |||||||||||
Income (loss) before income taxes | -701 | 798 | |||||||||
Depreciation and amortization | 3,710 | 4,057 | |||||||||
Operating segments | Product | |||||||||||
Segment information | |||||||||||
Revenues | 7,789 | 6,191 | |||||||||
Income (loss) before income taxes | 6,681 | 5,307 | |||||||||
Depreciation and amortization | 502 | 551 | |||||||||
Corporate and Other | |||||||||||
Segment information | |||||||||||
Revenues | -7,789 | -6,191 | |||||||||
Income (loss) before income taxes | -45,878 | -40,507 | |||||||||
Depreciation and amortization | $181 | $3,457 |
Legal_Proceedings_Details
Legal Proceedings (Details) (USD $) | 0 Months Ended | |
In Thousands, except Share data, unless otherwise specified | Jan. 31, 2014 | 8-May-12 |
patent | ||
CardioNet | Mednet | ||
Legal proceedings | ||
Cash consideration paid under purchase agreement | $5,500 | |
Value of common stock issued for acquisition | 705 | |
CardioNet v. ScottCare Litigation | ||
Legal proceedings | ||
Number of patents allegedly infringed | 5 | |
Litigation settled | CardioNet v. Mednet Litigation | ||
Legal proceedings | ||
Number of patents infringed by the defendants | 5 | |
Litigation settled | CardioNet v. Mednet Litigation | Mednet | ||
Legal proceedings | ||
Cash consideration paid under purchase agreement | 5,500 | |
Shares of common stock issued under definitive stock purchase agreement | 96,649 | |
Assumed outstanding secured debt, including interest under definitive stock purchase agreement | $9,720 |
Legal_Proceedings_Details_2
Legal Proceedings (Details 2) (CardioNet, Inc. and Braemar Manufacturing, LLC, USD $) | Dec. 31, 2014 |
In Thousands, unless otherwise specified | |
CardioNet, Inc. and Braemar Manufacturing, LLC | |
Legal proceedings | |
Accrual of contingent liabilities | $0 |
Civil_Investigative_Demand_Det
Civil Investigative Demand (Details) (Civil Investigative Demand, USD $) | 6 Months Ended |
In Thousands, unless otherwise specified | Jun. 30, 2014 |
Civil Investigative Demand | |
Civil Investigative Demand | |
Amount of non-operating charge | $6,400 |
Quarterly_Financial_Data_Unaud2
Quarterly Financial Data (Unaudited) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Quarterly Financial Data (Unaudited) | |||||||||||
Total revenues | $43,653 | $43,113 | $42,650 | $37,162 | $33,105 | $31,874 | $32,104 | $32,418 | $166,578 | $129,501 | $111,494 |
Gross profit | 24,529 | 23,678 | 23,613 | 21,644 | 20,795 | 19,234 | 19,496 | 19,545 | 93,464 | 79,070 | 65,901 |
Integration, restructuring and other charges | 2,073 | 1,045 | 1,000 | 2,980 | 1,162 | 3,077 | 2,541 | 1,202 | 7,098 | 7,982 | 4,236 |
(Loss) income from operations | -702 | 486 | -401 | -3,696 | 226 | -2,835 | -2,238 | -2,034 | -4,313 | -6,881 | -13,159 |
Net loss | ($1,654) | ($29) | ($3,988) | ($4,122) | $23 | ($2,956) | ($2,299) | ($2,087) | ($9,793) | ($7,319) | ($12,202) |
Basic and diluted net loss per share | ($0.06) | $0 | ($0.15) | ($0.16) | $0 | ($0.12) | ($0.09) | ($0.08) | ($0.37) | ($0.29) | ($0.49) |
Schedule_IIAllowance_for_Doubt1
Schedule II-Allowance for Doubtful Accounts (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Allowance for Doubtful Accounts | |||
Beginning Balance | $7,640 | $7,617 | $9,889 |
Additions Charged To Expense | 9,347 | 7,787 | 11,912 |
Deductions From Reserve | -6,325 | -7,763 | -14,184 |
Ending Balance | $10,662 | $7,640 | $7,617 |